エビデンスに基づいた癌化学療法ハンドブック　2018

出版社： メディカルレビュー社
著者：
発行日： 2018-06-10
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784779220807
電子書籍版： 2018-06-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

商品紹介

肺癌から白血病、悪性リンパ腫まで、各癌領域における化学療法についてまとめたハンドブック。治療レジメン、治療成績やその療法の特徴、主な副作用とその対策などを掲載。エビデンスとなる原典も当該療法ごとに示す。

目次

  • 序章　分子標的治療の新展開―免疫チェックポイント阻害療法時代を迎えて―
    第１章　肺癌―小細胞肺癌／非小細胞肺癌
    第２章　乳癌
    第３章　胃癌
    第４章　結腸・直腸癌
    第５章　食道癌
    第６章　肝細胞癌／胆道癌／膵癌
    第７章　婦人科癌
    第８章　泌尿器癌
    第９章　頭頸部癌
    第10章　整形外科腫瘍
    第11章　悪性黒色腫
    第12章　白血病
    第13章　多発性骨髄腫
    第14章　悪性リンパ腫
    第15章　化学療法の副作用に対する薬物による支持療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章 分子標的治療の新展開 - 免疫チェックポイント阻害療法時代を迎えて -

P.13 掲載の参考文献
1) Kohno T, Ichikawa H, Totoki Y, et al : KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012 ; 18 : 375-7.
PubMed
2) Takeuchi K, Soda M, Togashi Y, et al : RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012 ; 18 : 378-81.
PubMed
3) Lipson D, Capelletti M, Yelensky R, et al : Identifi-cation of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012 ; 18 : 382-4.
 
4) Kohno T, Tsuta K, Tsuchihara K, et al : RET fusion gene : translation to personalized lung cancer therapy. Cancer Sci. 2013 ; 104 : 1396-400.
PubMed
5) Yoh K, Seto T, Satouchi M, et al : Vandetanib in patients with previously treated RET-rearranged advanced non-small cell lung cancer (LURET) : an open-label, multicenter phase 2 trial. Lancet Respir Med. 2017 ; 5 : 42-50.
PubMed
6) Shaw AT, Ou SH, Bang YJ, et al : Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 ; 371 : 1963-71.
PubMed
7) Mok TS, Wu YL, Ahn MJ, et al : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 ; 376 : 629-40.
 
8) Soria JC, Ohe Y, Vansteenkiste J, et al : Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 ; 378 : 113-25.
PubMed
9) Hida T, Nokihara H, Kondo M, et al : Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial. Lancet. 2017 ; 390 : 29-39.
PubMed
10) Topalian SL, Hodi FS, Brahmer JR, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.
PubMed
11) Brahmer J, Reckamp KL, Baas P, et al : Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 123-35.
PubMed
12) Borghaei H, Paz-Ares L, Horn L, et al : Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 1627-39.
PubMed
13) Herbst RS, Baas P, Kim DW, et al : Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomized controlled trial. Lancet. 2016 ; 387 : 1540-50.
PubMed
14) Rittmeyer A, Barlesi F, Waterkamp D, et al : Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer (OAK) : a phase 3, open-label, multicenter randomised controlled trial. Lancet. 2017 ; 389 : 255-65.
 
15) Reck M, Rodriguez-Abreu D, Robinson AG, et al : Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 ; 375 : 1823-33.
PubMed

第1章 肺癌

P.26 掲載の参考文献
1) Toyoda Y, Nakayama T, Ioka A, et al. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol. 2008 ; 38 : 534-9.
PubMed
2) 厚生労働省. 平成28年人口動態統計. 2017.
 
3) Masters GA. Clinical Presentation of Small Cell Lung Cancer. In : Pass HI DPC, Johnson DH, Minna JD, et al (ed). Principles and Practice of Lung Cancer : The Official Reference Text of the IASLC, Edition 4th. Philadelphia : Lippincott Williams & Wilkins ; 2010. p.341.
 
4) Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med. 1969 ; 46 : 516-25.
PubMed
5) Goldstraw P. The International Staging System for Lung Cancer. In : Pass HI DPC, Johnson DH, Minna JD, et al, editors. Principles and Practice of Lung Cancer : The Official Reference Text of the IASLC, Edition 4th. Philadelphia : Lippincott ; Williams & Wilkins ; 2010. p.437.
 
6) Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet. 1973 ; 2 : 63-5.
PubMed
7) Einhorn LH, Fee WH, Farber MO, et al. Improved chemotherapy for small-cell undifferentiated lung cancer. JAMA. 1976 ; 235 : 1225-9.
PubMed
8) Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase 2 trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage 1-3a small cell lung cancer : the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005 ; 129 : 977-83.
 
9) Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 ; 327 : 1618-24.
PubMed
10) Takada M, Fukuoka M, Kawahara M, et al. Phase 3 study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer : results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002 ; 20 : 3054-60.
 
11) Turrisi AT, 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 ; 340 : 265-71.
PubMed
12) Faivre-Finn C, Snee M, Blackhall FH. CONVERT : An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). J Clin Oncol. 2016 ; 34 (suppl ; abstr 8504).
 
13) Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202) : a randomised phase 3 study. Lancet Oncol. 2014 ; 15 : 106-13.
PubMed
14) Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 ; 83 : 855-61.
PubMed
15) Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer : a phase 3 trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992 ; 10 : 282-91.
 
16) Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 ; 346 : 85-91.
PubMed
17) Hanna N, Bunn PA, Jr., Langer C, et al. Randomized phase 3 trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 ; 24 : 2038-43.
PubMed
18) Lara PN, Jr., Natale R, Crowley J, et al. Phase 3 trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer : clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 ; 27 : 2530-5.
PubMed
19) Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase 3 study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease Ann Oncol. 2010 ; 21 : 1810-6.
PubMed
20) Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010 ; 5 : 867-73.
 
21) Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer : JCOG 0509. J Clin Oncol. 2014 ; 32 : 1262-8.
PubMed
22) Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer : a phase 3 randomised controlled trial. Lancet. 2015 ; 385 : 36-42.
PubMed
23) Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol. 1998 ; 16 : 2126-32.
 
24) Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1989 ; 59 : 584-90.
 
25) Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer : a Cancer Research Campaign trial. Br J Cancer. 1989 ; 59 : 578-83.
PubMed
26) Veslemes M, Polyzos A, Latsi P, et al. Optimal duration of chemotherapy in small cell lung cancer : a randomized study of 4 versus 6 cycles of cisplatin-etoposide. J Chemother. 1998 ; 10 : 136-40.
PubMed
27) Han JY, Kim HT, Lim KY, et al. Randomized phase 2 study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer. J Thorac Oncol. 2008 ; 3 : 1039-45.
 
28) Chao H, Huang FAS, Karen Kelly. Clinical Presentation of Small Cell Lung Cancer. In : Pass HI DPC, Johnson DH, Minna JD, et al, editors. Principles and Practice of Lung Cancer : The Official Reference Text of the IASLC, Edition 4th. Philadelphia : Lippincott Williams & Wilkins ; 2010. p.847.
 
29) Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032) : a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 ; 17 : 883-95.
PubMed
30) Reck M, Luft A, Szczesna A, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 ; 34 : 3740-8.
PubMed
31) Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer : a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017 ; 18 : 42-51.
PubMed
32) Safont MJ, Artal-Cortes A, Sirera R, et al. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. Lung Cancer. 2009 ; 63 : 83-7.
PubMed
33) Sakuragi T, Oshita F, Nagashima S, et al. Retrospective analysis of the treatment of patients with small cell lung cancer showing poor performance status. Jpn J Clin Oncol. 1996 ; 26 : 128-33.
PubMed
34) Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer : JCOG 9702. Br J Cancer. 2007 ; 97 : 162-9.
PubMed
35) Sekine I, Okamoto H, Horai T, et al. A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. Clin Lung Cancer. 2014 ; 15 : 96-102.
PubMed
36) Batist G, Carney DN, Cowan KH, et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer : clinical trial and in vitro correlates. J Clin Oncol. 1986 ; 4 : 982-6.
PubMed
37) Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer : the influence of prior chemotherapy. J Clin Oncol. 1988 ; 6 : 1264-70.
PubMed
38) Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer : a phase II trial. J Clin Oncol.1990 ; 8 : 1613-7.
PubMed
39) Ebi N, Kubota K, Nishiwaki Y, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol. 1997 ; 27 : 166-9.
PubMed
40) O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006 ; 24 : 5441-7.
PubMed
41) von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999 ; 17 : 658-67.
PubMed
42) von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014 ; 32 : 4012-9.
PubMed
43) Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605) : a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016 ; 17 : 1147-57.
PubMed
44) Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996 ; 14 : 2785-90.
PubMed
45) Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer : a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997 ; 15 : 2090-6.
 
46) Murakami H, Yamamoto N, Shibata T, et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer : Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 2014 ; 84 : 67-72.
 
47) Onoda S, Masuda N, Seto T, et al. Phase 2 trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer : Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006 ; 24 : 5448-53.
PubMed
48) Kato T, Nokihara H, Ohe N, et al. Phase 2 trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts). 2006 ; 24 : 7061.
 
49) Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 ; 341 : 476-84.
 
50) Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007 ; 357 : 664-72.
PubMed
51) Seto T, Takahashi T, Yamanaka, T et al. Prophylactic cranial irradiation has a detrimental effect on the overall survival of patients with extensive disease small cell lung cancer : Results of a Japanese randomized phase III trial. J Clin Oncol. 2014 ; 32 (suppl ; abstr 7503)
 
52) Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01) : a randomised clinical trial. Lancet Oncol. 2009 ; 10 : 467-74.
PubMed
P.37 掲載の参考文献
1) Takada M, et al. J Clin Oncol. 2002 ; 20 : 3054-60.
PubMed
2) Fried DB, et al. J Clin Oncol. 2004 ; 22 : 4837-45.
PubMed
3) Turrisi AT, et al. N Engl J Med. 1999 ; 340 : 265-71.
PubMed
4) Auperin A, et al. N Engl J Med. 1999 ; 341 : 476-84.
PubMed
P.40 掲載の参考文献
1) Kudoh S, et al. J Clin Oncol. 1998 ; 16 : 1068-74.
PubMed
2) Noda K, et al. N Engl J Med. 2002 ; 346 : 85-91.
PubMed
3) Satouchi M, et al. J Clin Oncol. 2014 ; 32 : 1262-8.
PubMed
4) Lara PN Jr, et al. J Clin Oncol. 2009 ; 27 : 2530-5.
PubMed
5) Shao N, et al. J Thorac Oncol. 2012 ; 7 : 470-2.
PubMed
P.43 掲載の参考文献
1) Noda K, et al. N Engl J Med. 2002 ; 346 : 85-91.
PubMed
2) Lara PN Jr, et al. J Clin Oncol. 2009 ; 27 : 2530-5.
PubMed
3) Hanna N, et al. J Clin Oncol. 2006 ; 24 : 2038-43.
 
P.46 掲載の参考文献
1) Okamoto H, et al. J Clin Oncol. 1999 ; 17 : 3540-5.
PubMed
2) Okamoto H, et al. Br J Cancer. 2007 ; 97 : 162-9.
PubMed
P.49 掲載の参考文献
1) von Pawel J, et al. J Clin Oncol. 2014 ; 32 : 4012-9.
PubMed
2) Murakami H, et al. Lung Cancer. 2014 ; 84 : 67-72.
PubMed
3) Sekine I, et al. Clin Lung Cancer. 2014 ; 15 : 96-102.
PubMed
P.52 掲載の参考文献
1) Von Pawel J, et al. J Clin Oncol. 1999 ; 17 : 658-67.
PubMed
2) Goto K, et al. Lancet Oncol. 2016 ; 17 : 1147-57.
PubMed
P.55 掲載の参考文献
1) Sekine I, et al. Br J Cancer. 2003 ; 88 : 808-13.
PubMed
2) Goto K, et al. Br J Cancer. 2004 ; 91 : 659-65.
PubMed
3) Goto K, et al. Lancet Oncol. 2016 ; 17 : 1147-57.
PubMed
P.68 掲載の参考文献
1) Chemotherapy in non-small cell lung cancer : a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995 ; 311 : 899-909.
 
2) Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan. Ann Oncol. 2007 ; 18 : 317-23.
PubMed
3) Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 ; 16 : 1630-8.
PubMed
4) Rangachari D, VanderLaan PA, Shea M, et al. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 > 50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 ; 12 : 878-83.
PubMed
5) Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol. 2010 ; 11 : 121-8.
PubMed
6) Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 ; 362 : 2380-8.
 
7) Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015 ; 26 : 1877-83.
 
8) Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatinbased chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 ; 16 : 141-51.
PubMed
9) Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) : an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 ; 15 : 1236-44.
 
10) Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 ; 16 : 830-8.
PubMed
11) Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 201 ; 376 : 629-40.
 
12) Yoshida K, Ohe Y, Inoue A, et al. Overall survival of EGFR mutation positive non-small cell lung cancer patients : Real-world treatment patterns of 1,660 Japanese patients. WCLC 2016.
 
13) Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 ; 371 : 2167-77.
PubMed
14) Hida T, Nokihara H, Kondo M, et al. Randomized phase 3 of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lancet. 2017 ; 390 : 29-39.
PubMed
15) Scagliotti G, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with advanced ALK + NSCLC previously treated with chemotherapy and crizotinib : Reslts from the confiematory phase III ASCEND-5 study. ESMO meeting 2016 Abstracts LBA42.
 
16) Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer : A Phase II Global Study. J Clin Oncol. 2016 ; 34 : 661-8.
PubMed
17) Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer : a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 ; 17 : 234-42.
PubMed
18) Ito K, Hataji O, Kobayashi H, et al. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study. J Thorac Oncol. 2017 ; 12 : 390-96.
PubMed
19) Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 ; 368 : 2385-94.
PubMed
20) Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 ; 371 : 1963-71.
PubMed
21) Goto K, Yang JC, Kim DW, et al. Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). ASCO meeting 2016 ; Abstracts 34 : 9022
 
22) Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 ; 375 : 1823-1833.
PubMed
23) Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial. Lancet. 2016 ; 387 : 1540-50.
PubMed
24) Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 1627-39.
PubMed
25) Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9 ; 373 (2) : 123-35.
PubMed
26) Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK) : a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 ; 389 : 255-65.
 
27) Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet. 201 ; 384 : 665-73.
 
28) Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 ; 26 : 3543-51.
PubMed
29) Patel JD, Socinski MA, Garon EB, et al. PointBreak : a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 ; 31 : 4349-57.
PubMed
30) Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small-cell lung cancer : updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 ; 25 (5) : 1044-52.
PubMed
31) Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT : Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 ; 31 : 2895-902.
PubMed
32) Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 ; 355 : 2542-50.
PubMed
33) Zhou C, Wu YL, Chen G, et al. BEYOND : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 ; 33 : 2197-204.
 
34) Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer : results of a west Japan oncology group study. J Clin Oncol. 2010 ; 28 : 5240-6.
 
35) Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer : TCOG0701 CATS trial. Ann Oncol. 2015 ; 26 : 1401-8.
 
36) Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nabpaclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer : final results of a phase III trial. J Clin Oncol. 2012 ; 30 : 2055-62.
PubMed
37) Shukuya T, Yamanaka T, Seto T, et al. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 ; 16 : 1630-8.
PubMed
38) Nishio M, Mok T, Nakagawa K, et al. Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment-East Asian S-1 Trial-Lung Cancer (EAST-LC) -. ESMO 2016
 
P.76 掲載の参考文献
1) Maemondo M, et al. N Engl J Med. 2010 ; 362 : 2380-8.
PubMed
2) Mitsudomi T, et al. Lancet Oncol. 2010 ; 11 : 121-8.
PubMed
3) Zhou C, et al. Lancet Oncol. 2011 ; 12 : 735-42.
PubMed
4) Rosell R, et al. Lancet Oncol. 2012 ; 13 : 239-46.
PubMed
5) Seto T, et al. Lancet Oncol. 2014 ; 15 : 1236-44.
PubMed
6) Inoue A, et al. J Clin Oncol. 2009 ; 27 : 1394-400.
PubMed
7) Akamatsu H, et al. Respiratory investigation. 2015 ; 53 : 68-72.
PubMed
P.79 掲載の参考文献
1) Yang JC, et al. Lancet Oncol. 2015 ; 16 : 141-51.
PubMed
2) Park K, et al. Lancet Oncol. 2016 ; 17 : 577-89.
PubMed
3) Yang JC, et al. Lancet Oncol. 2015 ; 16 : 830-8.
PubMed
4) Kato T, et al. Cancer Sci. 2015 ; 106 : 1202-11.
PubMed
P.82 掲載の参考文献
1) Janne PA, et al. N Engl J Med. 2015 ; 372 : 1689-99.
PubMed
2) Yang J, et al. J Thorac Oncol. 2016 ; 11 (suppl ; abstr LBA2_PR).
 
3) Yu HA, et al. Clin Cancer Res. 2013 ; 19 : 2240-7.
 
4) Cross DA, et al. Cancer Discov. 2014 ; 4 : 1046-61.
PubMed
P.84 掲載の参考文献
1) Borghaei H, et al. N Engl J Med. 2015 ; 373 : 1627-39.
PubMed
2) Brahmer J, et al. N Engl J Med. 2015 ; 373 : 123-35.
PubMed
3) Champiat S, et al. Ann Oncol. 2016 ; 27 : 559-74.
PubMed
P.87 掲載の参考文献
1) Herbst RS, et al. Lancet. 2016 ; 387 : 1540-50.
PubMed
2) Reck M, et al. N Engl J Med. 2016 ; 375 : 1823-33.
PubMed
3) Garon ER, et al. N Engl J Med. 2015 ; 372 : 2018-28.
 
4) Freshwater T, et al. Presented at the 6th American Conference on Pharmacometrics (#M-11). Arlington, VA, October 3-7, 2015.
 
P.90 掲載の参考文献
1) Fehrenbacher L, et al. Lancet. 2016 ; 387 : 1837-46.
PubMed
2) Rittmeyer A, et al. Lancet. 2017 ; 389 : 255-65.
PubMed
3) Khunger M, et al. Chest. 2017 ; 152 : 271-81.
PubMed
P.95 掲載の参考文献
1) Scagliotti GV, et al. J Clin Oncol. 2008 ; 26 : 3543-51.
PubMed
2) Paz-Ares LG, et al. J Clin Oncol. 2013 ; 31 : 2895-902.
PubMed
3) Zukin M, et al. J Clin Oncol. 2013 ; 31 : 2849-53.
PubMed
4) Hanna N, et al. J Clin Oncol. 2004 ; 22 : 1589-97.
 
5) Ciuleanu T, et al. Lancet. 2009 ; 374 : 1432-40.
PubMed
P.100 掲載の参考文献
1) Sandler A, et al. N Engl J Med. 2006 ; 355 : 2542-50.
 
2) Niho S, et al. Lung Cancer. 2012 ; 76 : 362-7.
PubMed
3) Zhou C, et al. J Clin Oncol. 2015 ; 33 : 2197-204.
 
4) Patel JD, et al. J Clin Oncol. 2013 ; 31 : 4349-57.
PubMed
5) F. Barlesi, et al. Ann Oncol. 2014 ; 25 : 1044-52.
 
6) Spigel DR, et al. J Thorac Oncol. 2015 ; 10 : 353-9.
PubMed
7) Hirai F, et al. Oncol Lett. 2015 ; 9 : 2577-82.
PubMed
8) Usui K, et al. Lung Cancer. 2016 ; 99 : 131-6.
PubMed
P.103 掲載の参考文献
1) Schiller JH, et al. N Engl J Med. 2002 ; 346 : 92-8.
PubMed
2) Ohe Y, et al. Ann Oncol. 2007 ; 18 : 317-23.
PubMed
3) Quoix E, et al. Lancet. 2011 ; 378 : 1079-88.
PubMed
P.107 掲載の参考文献
1) Okamoto I, et al. J Clin Oncol. 2010 ; 28 : 5240-6.
PubMed
2) Kubota K, et al. Ann Oncol. 2015 ; 26 : 1401-8.
PubMed
P.110 掲載の参考文献
1) Kubota K, et al. J Clin Oncol. 2004 ; 22 : 254-61.
 
2) Shepherd FA, et al. J Clin Oncol. 2000 ; 18 : 2095-103.
PubMed
3) Fossella F, et al. J Clin Oncol. 2003 ; 21 : 3016-24.
PubMed
4) Douillard JY, et al. J Thorac Oncol. 2007 ; 2 : 939-46.
PubMed
P.114 掲載の参考文献
1) Baggstrom MQ, et al. J Thorac Oncol. 2007 ; 2 : 845-53.
PubMed
2) Hotta K, et al. Ann Oncol. 2004 ; 15 : 1782-9.
PubMed
3) Schiller JH, et al ; Eastern Cooperative Oncology Group. N Engl J Med. 2002 ; 346 ; 92-8.
 
4) Ohe Y, et al. Ann Oncol. 2007 ; 18 : 317-23.
PubMed
5) Le Chevalier T, et al. Lung Cancer. 2005 ; 47 : 69-80.
PubMed
6) 日本肺癌学会 (編). 肺癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.
 
7) Reck M, et al ; BO17704 Study Group. Ann Oncol. 2010 ; 21 : 1804-9.
 
8) 日本癌治療学会 (編). 制吐薬適正使用ガイドライン 2015年10月第2版. 東京 : 金原出版 ; 2015.
 
P.118 掲載の参考文献
1) Ohe Y, et al. Ann Oncol. 2007 ; 18 : 317-23.
PubMed
2) Pignon JP, et al. J Clin Oncol. 2008 ; 26 : 3552-9.
PubMed
3) The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999 ; 91 : 66-72.
 
4) Kudoh S, et al. J Clin Oncol. 2006 ; 24 : 3657-63.
PubMed
5) Douillard JY, et al. J Thorac Oncol. 2010 ; 5 : 220-8.
PubMed
P.121 掲載の参考文献
1) Negoro S, et al. Br J Cancer. 2003 ; 88 : 335-41.
PubMed
2) Benson AB 3rd, et al. J Clin Oncol. 2004 ; 22 : 2918-26.
PubMed
3) Ohe Y, et al. Ann Oncol. 2007 ; 18 : 317-23.
PubMed
P.124 掲載の参考文献
1) Shukuya T, et al. Lancet Oncol. 2015 ; 16 : 1630-8.
PubMed
P.127 掲載の参考文献
1) Shaw AT, et al. N Engl J Med. 2013 ; 368 : 2385-94.
PubMed
2) Solomon BJ, et al. N Engl J Med. 2014 ; 371 : 2167-77.
PubMed
3) Nokihara H, et al. J Clin Oncol. 2016 ; 34 (suppl ; abstr 9008).
 
4) Shaw AT, et al. N Engl J Med. 2014 ; 371 : 1963-71.
PubMed
P.130 掲載の参考文献
1) Seto T, et al. Lancet Oncol. 2013 ; 14 : 590-8.
PubMed
2) Hida T, et al. Cancer Sci. 2016 ; 107 : 1642-6.
PubMed
3) Sakamoto H, et al. Cancer Cell. 2011 ; 19 : 679-90.
 
P.133 掲載の参考文献
1) Kim DW, et al. Lancet Oncol. 2016 ; 17 : 452-63.
PubMed
2) Scagliotti GV, et al. ESMO 2016. abstr LBA42.
 
3) Crino L, et al. J Clin Oncol. 2016 ; 34 : 2866-73.
PubMed
4) Nishio M, et al. J Thorac Oncol. 2015 ; 10 : 1058-66.
 
5) De Castro Jr G, et al. WCLC 2016, PL03.07
 
P.137 掲載の参考文献
1) Sekine I, Noda K, Oshita F, et al. Cancer Sci. 2004 ; 95 : 691-5.
PubMed
2) Shukuya T, Takahashi T, Harada H, et al. Anticancer Res. 2012 ; 32 : 675-80.
PubMed
3) Naito Y, Kubota K, Nihei K, et al. J Thorac Oncol. 2008 ; 3 : 617-22.
PubMed
4) Hughes BG, Ahern E, Lehman M, et al. Asia Pac J Clin Oncol. 2017 ; 13 : 137-44.
PubMed
5) Singhal N, Mislang A, Karapetis CS, et al. Anticancer Drugs. 2015 ; 26 : 1083-8.
PubMed
P.141 掲載の参考文献
1) Belani CP, et al. J Clin Oncol. 2005 ; 23 : 5883-91.
PubMed
2) Endo M, et al. Radiat Med. 2005 ; 23 : 331-5.
PubMed
3) Yamamoto N, et al. J Clin Oncol. 2010 ; 28 : 3739-45.
PubMed
P.144 掲載の参考文献
1) Socinski MA, et al. Ann Oncol. 2013 ; 24 : 314-21.
PubMed
2) Socinski MA, et al. Ann Oncol. 2013 ; 24 : 2390-6.
PubMed
3) Satouchi M, et al. Lung cancer. 2013 ; 81 : 97-101.
PubMed
P.146 掲載の参考文献
1) Yoh K, et al. Lung Cancer. 2016 ; 99 : 186-93.
PubMed
2) Garon EB, et al. Lancet. 2014 ; 384 : 665-73.
PubMed
3) Perol M, et al. Lung Cancer. 2016 ; 93 : 95-103.
 

第2章 乳癌

P.161 掲載の参考文献
1) Bonadonna G, et al. N Engl J Med. 1976 ; 294 : 405-10.
PubMed
2) Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2012 ; 379 : 432-44.
 
3) Sparano JA, et al. N Engl J Med. 2008 ; 358 : 1663-71.
PubMed
4) Citron ML, et al. J Clin Oncol. 2003 ; 21 : 1431-9.
PubMed
5) Bonilla L, et al. J Natl Cancer Inst. 2010 ; 102 : 1845-54.
 
6) Jones SE, et al. J Clin Oncol. 2006 ; 24 : 5381-7.
PubMed
7) Muss HB, et al. N Engl J Med. 2009 ; 360 : 2055-65.
PubMed
8) Masuda N, et al. N Engl J Med. 2017 ; 376 : 2147-59.
PubMed
9) Wolmark N, et al. J Natl Cancer Inst Monogr. 2001 ; 30 : 96-102.
PubMed
10) Mieog JS, et al. Cochrane Database Syst Rev. 2007 ; 2 : CD005002.
PubMed
11) Rastogi P, et al. J Clin Oncol. 2008 ; 26 : 778-85.
PubMed
12) Romond EH, et al. N Engl J Med. 2005 ; 353 : 1673-84.
PubMed
13) Perez EA, et al. J Clin Oncol. 2011 ; 29 : 4491-7.
PubMed
14) Piccart-Gebhart MJ, et al. N Engl J Med. 2005 ; 353 : 1659-72.
PubMed
15) Slamon D, et al. N Engl J Med. 2011 ; 365 : 1273-83.
PubMed
16) Joensuu H, et al. N Engl J Med. 2006 ; 354 : 809-20.
PubMed
17) Spielmann M, et al. J Clin Oncol. 2009 ; 27 : 6129-34.
PubMed
18) Paik S, et al. J Clin Oncol. 2006 ; 24 : 3726-34.
 
19) Pagani O, et al. N Engl J Med. 2014 ; 371 : 107-18.
PubMed
20) Gnant M, et al. Lancet Oncol. 2011 ; 12 : 631-41.
PubMed
21) Francis PA, et al. N Engl J Med. 2015 ; 372 : 436-46.
PubMed
22) fleming G, et al. SABCS 2017 ; GS4-03.
 
23) Stopeck AT, et al. J Clin Oncol. 2010 ; 28 : 5132-9.
PubMed
24) Finn RS, et al. N Engl J Med. 2016 ; 375 : 1925-36.
PubMed
25) Baselga J, et al. N Engl J Med. 2012 ; 366 : 109-19.
PubMed
26) Ellis PA, et al. ASCO 2015 ; abst 507.
 
27) Verma S, et al. N Engl J Med. 2012 ; 367 : 1783-91.
 
28) von Minckwitz G, et al. J Clin Oncol. 2009 ; 27 : 1999-2006.
PubMed
29) Cortes J, et al. Lancet. 2011 ; 377 : 914-23.
PubMed
P.165 掲載の参考文献
1) Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2012 ; 379 : 432-44.
 
2) Jacobs SA, et al. 37th SABCS 2014 ; Abstract S3-02.
 
3) Henderson IC, et al. J Clin Oncol. 2003 ; 21 : 976-83.
PubMed
4) Navari RM, et al. J Support Oncol. 2011 ; 9 : 188-95.
PubMed
5) Navari RM, et al. N Engl J Med. 2016 ; 375 : 134-42.
PubMed
P.168 掲載の参考文献
1) Citron ML, et al. J Clin Oncol. 2003 ; 21 : 1431-9.
PubMed
2) Bonilla L, et al. J Natl Cancer Inst. 2010 ; 102 : 1845-54.
 
3) Burstein HJ, et al. J Clin Oncol. 2005 ; 23 : 8340-7.
PubMed
P.171 掲載の参考文献
1) Coombes RC, et al. J Clin Oncol. 1996 ; 14 : 35-45.
PubMed
2) Bonneterre J, et al. J Clin Oncol. 2005 ; 23 : 2686-93.
PubMed
3) Jacobs A, et al. 37th SABCS 2014 ; Abstract S3-02.
 
P.174 掲載の参考文献
1) Bonadonna G, et al. N Engl J Med. 1976 ; 294 : 405-10.
PubMed
2) Bonadonna G, et al. BMJ. 2005 ; 330 : 217.
PubMed
3) Fisher B, et al. J Clin Oncol. 1990 ; 8 : 1483-96.
 
4) Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 ; 352 : 930-42.
 
5) Ohashi Y, et al. Breast Cancer Res Treat. 2010 ; 119 : 633-41.
PubMed
6) Tada K, et al. Breast Cancer. 2006 ; 13 : 279-83.
PubMed
P.178 掲載の参考文献
1) Swain SM, et al. N Engl J Med. 2010 ; 362 : 2053-65.
PubMed
2) Eiermann W, et al. J Clin Oncol. 2011 ; 29 : 3877-84.
PubMed
3) von Minckwitz G, et al. J Natl Cancer Inst. 2008 ; 100 : 552-62.
PubMed
4) von Minckwitz G, et al. J Clin Oncol. 2013 ; 31 : 3623-30.
PubMed
5) Martin M, et al. N Engl J Med. 2005 ; 352 : 2302-13.
 
6) von Minckwitz G, et al. Ann Oncol. 2008 ; 19 : 292-8.
 
P.181 掲載の参考文献
1) Jones SE, et al. J Clin Oncol. 2006 ; 24 : 5381-7.
PubMed
2) Jones S, et al. J Clin Oncol. 2009 ; 27 : 1177-83.
 
3) Jones SE, et al. Lancet Oncol. 2013 ; 14 : 1121-8.
PubMed
4) Kosaka Y, et al. Support Care Cancer. 2015 ; 23 : 1137-43.
PubMed
P.184 掲載の参考文献
1) Sparano JA, et al. N Engl J Med. 2008 ; 358 : 1663-71.
PubMed
2) 中村清吾, 他. 乳癌の臨床. 2008 : 23 : 111-7.
Medical*Online
3) Harvey V, et al. J Clin Oncol. 2006 ; 24 : 4963-70.
 
P.187 掲載の参考文献
1) Katsumata N, et al. Ann Oncol. 2009 ; 20 : 1210-5.
PubMed
2) Harvey V, et al. J Clin Oncol. 2006 ; 24 : 4963-70.
 
3) Watanabe T, et al. Cancer Res. 2009 ; 69 (2 Suppl) : abst nr 4103.
 
4) Toi M, et al. Breast Cancer Res Treat. 2008 ; 110 : 531-9.
PubMed
P.190 掲載の参考文献
1) Citron ML, et al. J Clin Oncol. 2003 ; 21 : 1431-9.
PubMed
2) Del Mastro L, et al. Lancet. 2015 ; 385 : 1863-72.
PubMed
3) Budd GT, et al. J Clin Oncol. 2015 ; 33 : 58-64.
PubMed
P.193 掲載の参考文献
1) Sparano JA, et al. N Engl J Med. 2008 ; 358 : 1663-71.
PubMed
2) Martin M, et al. J Natl Cancer Inst. 2008 ; 100 : 805-14.
 
3) Seidman AD, et al. J Clin Oncol. 2008 ; 26 : 1642-9.
PubMed
P.196 掲載の参考文献
1) Gradishar WJ, et al. J Clin Oncol. 2005 ; 23 : 7794-803.
PubMed
2) Gradishar WJ, et al. J Clin Oncol. 2009 ; 27 : 3611-9.
PubMed
3) Rugo HS, et al. J Clin Oncol. 2015 ; 33 : 2361-9.
PubMed
4) Tsuyuki S, et al. Breast Cancer Res Treat. 2016 ; 160 : 61-7.
PubMed
P.199 掲載の参考文献
1) Cortes J, et al. Lancet. 2011 ; 377 : 914-23.
PubMed
2) Kaufman PA, et al. J Clin Oncol. 2015 ; 33 : 594-601.
PubMed
3) Iwata H, et al. J Clin Oncol. 2010 : 28 suppl ; abstr 1081.
 
4) 日本臨床腫瘍学会 (編). 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 : 南江堂 ; 2012.
 
5) NCCN Clinical Practice Guideline in Oncology(TM) Antiemesis Ver 1. 2012
 
P.201 掲載の参考文献
1) Toi M, et al. Jpn J Clin Oncol. 2005 ; 35 : 310-5.
PubMed
2) Terenziani M, et al. Breast Cancer Res Treat. 1996 ; 39 : 285-91.
PubMed
3) Burstein HJ, et al. J Clin Oncol. 2001 ; 19 : 2722-30.
 
4) Seo HY, et al. Invest New Drugs. 2011 ; 29 : 360-5.
PubMed
5) 日本臨床腫瘍学会 (編). 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 : 南江堂 ; 2012.
 
6) NCCN Clinical Practice Guideline in Oncology(TM) Antiemesis Ver 1. 2012
 
P.205 掲載の参考文献
1) Piccart-Gebhart MJ, et al. N Engl J Med. 2005 ; 353 : 1659-72.
PubMed
2) Romond EH, et al. N Engl J Med. 2005 ; 353 : 1673-84.
PubMed
3) Pivot X, et al. Lancet Oncol. 2013 ; 14 : 741-8.
PubMed
4) Inoue K, et al. Breast Cancer Res Treat. 2010 ; 119 : 127-36.
PubMed
5) von Minckwitz G, et al. J Clin Oncol. 2009 ; 27 : 1999-2006.
PubMed
P.208 掲載の参考文献
1) Romond EH, et al. N Engl J Med. 2005 ; 353 : 1673-84.
PubMed
2) Slamon D, et al. N Engl J Med. 2011 ; 365 : 1273-83.
PubMed
3) Tolaney SM, et al. N Engl J Med. 2015 ; 372 : 134-41.
PubMed
P.211 掲載の参考文献
1) Slamon D, et al. N Engl J Med. 2011 ; 365 : 1273-83.
PubMed
2) Slamon D, et al. San Antonio Breast Cancer Symposium, December 8-12. 2015. Publication number : S5-04.
 
P.214 掲載の参考文献
1) Swain SM, et al. N Engl J Med. 2015 ; 372 : 724-34.
PubMed
2) Baselga J, et al. N Engl J Med. 2012 ; 366 : 109-19.
PubMed
P.217 掲載の参考文献
1) Dang C, et al. J Clin Oncol. 2015 ; 33 : 442-7.
 
2) Smyth LM, et al. Breast Cancer Res Treat. 2016 ; 158 : 91-7.
PubMed
P.220 掲載の参考文献
1) Verma S, et al. N Engl J Med. 2012 ; 367 : 1783-91.
 
2) Krop IE, et al. Lancet Oncol. 2014 ; 15 : 689-99.
PubMed
3) LoRusso PM, et al. Clin Cancer Res. 2011 ; 17 : 6437-47.
PubMed
P.222 掲載の参考文献
1) Toi M, et al. Jpn J Clin Oncol. 2005 ; 35 : 310-5.
PubMed
2) Tokudome N, et al. Anticancer Drugs. 2008 ; 19 : 753-9.
 
3) Burstein HJ, et al. J Clin Oncol. 2001 ; 19 : 2722-30.
 
4) Andersson M, et al. J Clin Oncol. 2011 ; 29 : 264-71.
 
P.225 掲載の参考文献
1) von Minckwitz G, et al. J Clin Oncol. 2009 ; 27 : 1999-2006.
PubMed
2) Schaller G, et al. J Clin Oncol. 2007 ; 25 : 3246-50.
PubMed
P.228 掲載の参考文献
1) Geyer CE, et al. N Engl J Med. 2006 ; 355 : 2733-43.
PubMed
2) Cameron D, et al. Breast Cancer Res Treat. 2008 ; 112 : 533-43.
PubMed
3) Verma S, et al. N Engl J Med. 2012 ; 367 : 1783-91.
 
4) Bachelot T, et al. Lancet Oncol. 2013 ; 14 : 64-71.
PubMed
5) Scaltriti M, et al. Oncogene. 2009 ; 28 : 803-14.
PubMed
P.231 掲載の参考文献
1) Miller K, et al. N Engl J Med. 2007 ; 357 : 2666-76.
 
2) Miles D, et al. Eur J Cancer. 2017 ; 70 : 146-155.
PubMed
3) Aogi K, et al. Breast Cancer Res Treat. 2011 ; 129 : 829-38.
PubMed
4) Cameron D, et al. Lancet Oncol. 2013 ; 14 : 933-42.
PubMed
P.234 掲載の参考文献
1) Saeki T, et al. Breast Cancer. 2006 ; 13 : 49-57.
PubMed
2) Kusama M, et al. Breast Cancer. 2010 ; 17 : 233-40.
PubMed
3) Watanabe T, et al. Proc Am Soc Clin Oncol. 2001 ; 20 : 61b.
 
4) Blum JL, et al. J Clin Oncol. 1999 ; 17 : 485-93.
PubMed
5) Blum JL, et al. Cancer. 2001 ; 92 : 1759-68.
PubMed
6) Fumoleau P, et al. Eur J Cancer. 2004 ; 40 : 536-42.
PubMed
7) 松本光史, 他. 第14回日本乳癌学会総会. 2006 ; O-208.
 
P.237 掲載の参考文献
1) O'Shaughnessy J, et al. J Clin Oncol. 2002 ; 20 : 2812-23.
PubMed
2) Sato N, et al. San Antonio Breast Cancer Symposium. 2012.
 
P.240 掲載の参考文献
1) Takashima T, et al. Lancet Oncol. 2016 ; 17 : 90-8.
PubMed
2) Watanabe T, et al. SABCS. 2014 ; P3-10-01.
 
3) Shiroiwa T, et al. Qual Life Res. 2017 ; 26 : 445-53.
PubMed
4) Saeki T, et al. Breast Cancer. 2004 ; 11 : 194-202.
 
5) 佐伯俊昭, 他. 癌と化学療法. 2004 ; 31 : 539-47.
Medical*Online
6) Sato N, et al. San Antonio Breast Cancer Symposium. 2003 ; Abst 1078.
 
P.242 掲載の参考文献
1) Suzuki Y, et al. Jpn J Clin Oncol. 2009 ; 39 : 699-706.
PubMed
2) Earl HM, et al. Lancet Oncol. 2014 ; 15 : 201-12.
PubMed
3) Bear HD, et al. Lancet Oncol. 2015 ; 16 : 1037-48.
PubMed
4) Swain SM, et al. J Clin Oncol. 2013 ; 31 : 3197-204.
PubMed
P.245 掲載の参考文献
1) Albain KS, et al. J Clin Oncol. 2008 ; 26 : 3950-7.
PubMed
2) Aogi K, et al. Cancer Chemother Pharmacol. 2011 ; 67 : 1007-15.
PubMed
3) Park YH, et al. J Clin Oncol. 2013 ; 31 : 1732-9.
PubMed
P.248 掲載の参考文献
1) Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2011 ; 378 : 771-84.
 
2) Adjuvant Tamoxifen : Longer Against Shorter (ATLAS) Collaborative Group. Lancet. 2013 ; 381 : 805?16.
 
3) Gray RG, et al. J Clin Oncol. 2013 ; 31 (suppl : abstr 5).
 
P.252 掲載の参考文献
1) Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, et al. Lancet Oncol. 2008 ; 9 : 45-53.
 
2) Cuzick J, et al. Lancet Oncol. 2010 ; 11 : 1135-41.
PubMed
3) Aihara T, et al. Breast Cancer Res Treat. 2014 ; 148 : 337-43.
PubMed
4) Jakesz R, et al. J Natl Cancer Inst. 2007 ; 99 : 1845-53.
PubMed
5) Bonneterre J, et al. Cancer. 2001 ; 92 : 2247-58.
 
6) Milla-Santos A, et al. Am J Clin Oncol. 2003 ; 26 : 317-22.
PubMed
7) Sestak I, et al. J Clin Oncol. 2009 ; 27 : 4961-5.
PubMed
P.255 掲載の参考文献
1) Regan MM, et al. Lancet Oncol. 2011 ; 12 : 1101-8.
PubMed
2) Jin H, et al. J Clin Oncol. 2012 ; 30 : 718-21.
 
3) Goss PE, et al. N Engl J Med. 2016 ; 375 : 209-19.
PubMed
4) Mouridsen H, et al. J Clin Oncol. 2003 ; 21 : 2101-9.
PubMed
P.257 掲載の参考文献
1) van de Velde CJ, et al. Lancet. 2011 ; 377 : 321-31.
PubMed
2) Paridaens RJ, et al. J Clin Oncol. 2008 ; 26 : 4883-90.
PubMed
3) Goss PE, et al. J Clin Oncol. 2013 ; 31 : 1398-404.
PubMed
P.260 掲載の参考文献
1) Baselga J, et al. N Engl J Med. 2012 ; 366 : 520-9.
PubMed
2) Piccart M, et al. Ann Oncol. 2014 ; 25 : 2357-62.
PubMed
3) Rugo HS, et al. Ann Oncol. 2014 ; 25 : 808-15.
PubMed
P.263 掲載の参考文献
1) Di Leo A, et al. J Natl Cancer Inst. 2014 ; 106 : djt337.
 
2) Di Leo A, et al. J Clin Oncol. 2010 ; 28 : 4594-600.
 
3) Robertson JF, et al. Lancet. 2016 ; 388 : 2997-3005.
PubMed
P.266 掲載の参考文献
1) Francis PA, et al. N Engl J Med. 2015 ; 372 : 436-46.
PubMed
2) Klijn JG, et al. J Clin Oncol. 2001 ; 19 : 343-53.
 
P.268 掲載の参考文献
1) Pagani O, et al. N Engl J Med. 2014 ; 371 : 107-18.
PubMed
P.270 掲載の参考文献
1) Carlson RW, et al. J Clin Oncol. 2010 ; 28 : 3917-21.
PubMed
2) Nishimura R, et al. Oncol Rep. 2013 ; 29 : 1707-13.
PubMed
3) Masuda N, et al. Lancet Oncol. 2012 ; 13 : 345-52.
PubMed
4) Gnant M, et al. Ann Oncol. 2015 ; 26 : 313-20.
PubMed
P.273 掲載の参考文献
1) Johnson JR, et al. Br J Cancer. 1984 ; 50 : 363-6.
PubMed
2) Izuo M, et al. Breast Cancer Res Treat. 1981 ; 1 : 125-30.
PubMed
3) Muss HB, et al. J Clin Oncol. 1994 ; 12 : 1630-8.
PubMed
P.276 掲載の参考文献
1) Johnston S, et al. J Clin Oncol. 2009 ; 27 : 5538-46.
 
2) Balduzzi S, et al. Cochrane Database Syst Rev. 2014 ; 6 : CD006242.
PubMed
3) Chatsiproios D. Breast Care (Basel). 2010 ; 5 : 16-21.
PubMed
P.280 掲載の参考文献
1) Cristofanilli M, et al. Lancet Oncol. 2016 ; 17 : 425-39.
PubMed
2) Turner NC, et al. Ann Oncol. 2018 Jan 11. doi : 10.1093/annonc/mdx797. [Epub ahead of print]
 
3) Loibl S, et al. Oncologist. 2017 ; 22 : 1028-38.
PubMed
4) Iwata H, et al. J Glob Oncol. 2017 ; 3 : 289-303.
PubMed
5) Verma S, et al. Oncologist. 2016 ; 21 : 1165-1175.
PubMed
P.283 掲載の参考文献
1) Finn RS, et al. N Engl J Med. 2016 ; 375 : 1925-36.
PubMed
2) Turner NC, et al. Ann Oncol. 2018 Jan 11. doi : 10.1093/annonc/mdx797. [Epub ahead of print]
 
3) Rugo HS, et al. Ann Oncol. 2018 Jan 19. doi : 10.1093/annonc/mdy012. [Epub ahead of print]
 
4) Finn RS, et al. J Clin Oncol. 2017 ; 35 : suppl ; abstr 1001.
 
5) Masuda N, et al. Cancer Sci. 2018 ; 109 : 803-13.
PubMed

第3章 胃癌

P.294 掲載の参考文献
1) Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993 ; 72 : 37-41.
PubMed
2) Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 ; 8 : 163-8.
PubMed
3) Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 ; 71 : 587-91.
PubMed
4) Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer : the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003 ; 21 : 54-9.
 
5) Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol. 1994 ; 12 : 412-6.
PubMed
6) Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 ; 71 : 3813-8.
PubMed
7) Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer : a randomised phase 3 study. Lancet Oncol. 2009 ; 10 : 1063-9.
PubMed
8) Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol. 2008 ; 9 : 215-21.
 
9) Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer : a randomised phase III noninferiority trial. Ann Oncol. 2009 ; 20 : 666-73.
PubMed
10) Cunningham D, Okines AF, Ashley S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2010 ; 362 : 858-9.
PubMed
11) Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy- naive patients with advanced gastric cancer. Ann Oncol. 2015 ; 26 : 141-8.
 
12) Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group. J Clin Oncol. 2006 ; 24 : 4991-7.
 
13) Shirao K, Boku N, Yamada Y, et al. 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013 ; 43 : 972-80.
PubMed
14) Iwasa S, Goto M, Yasui H, et al. Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. Jpn J Clin Oncol. 2012 ; 42 : 787-93.
PubMed
15) Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer : A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 ; 47 : 2306-14.
 
16) Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer : A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 ; 30 : 1513-8.
PubMed
17) Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 ; 15 : 78-86.
PubMed
18) Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial. J Clin Oncol. 2013 ; 31 : 4438-44.
 
19) Shitara K, Takashima A, Fujitani K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE) : an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 ; 2 : 277-87.
PubMed
20) Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA) : a phase 3, open-label, randomised controlled trial. Lancet. 2010 ; 376 : 687-97.
PubMed
21) Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma : TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2016 ; 34 : 443-51.
 
22) Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations : TyTAN--a randomized, phase III study. J Clin Oncol. 2014 ; 32 : 2039-49.
PubMed
23) Kang YK, Shah MA, Ohtsu A, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol. 2016 ; 34 (suppl 4S ; abstr 5).
 
24) Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3) : a randomised, open-label phase 3 trial. Lancet Oncol. 2013 ; 14 : 481-9.
 
25) Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND) : a randomised, open-label phase 3 trial. Lancet Oncol. 2013 ; 14 : 490-9.
 
26) Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 ; 29 : 3968-76.
PubMed
27) Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) : a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 1224-35.
 
28) Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 ; 383 : 31-9.
PubMed
29) Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer : results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013 ; 31 : 3219-25.
 
30) Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer : results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 ; 31 : 3935-43.
PubMed
31) Cunningham D, Tebbutt NC, Davidenko I, et al. Phase III, randomized, double-blind, multicenter, placebo (P) -controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer : RILOMET-1 study. J Clin Oncol. 2015 ; 33 (suppl ; abstr 4000).
 
32) Shah MA, Bang YJ, Lordick F, et al. METGastric : A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). J Clin Oncol. 2015 ; 33 (suppl ; abstr 4012).
 
33) Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012) : a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016 ; 17 : 717-26.
PubMed
34) Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 ; 390 : 2461-71.
 
P.305 掲載の参考文献
1) Koizumi W, et al. Lancet Oncol. 2008 ; 9 : 215-21.
PubMed
2) Ryu MH, et al. Ann Oncol. 2015 ; 26 : 2097-101.
PubMed
3) Yamada Y, et al. Ann Oncol. 2015 ; 26 : 141-8.
PubMed
4) Bang YJ, et al. Lancet. 2010 ; 376 : 687-97.
PubMed
5) Ohtsu A, et al. J Clin Oncol. 2011 ; 29 : 3968-76.
PubMed
P.309 掲載の参考文献
1) Yamada Y, et al. Ann Oncol. 2015 ; 26 : 141-8.
PubMed
2) Cunningham D, et al. N Engl J Med. 2008 ; 358 : 36-46.
 
3) Kim GM, et al. Eur J Cancer. 2012 ; 48 : 518-26.
PubMed
P.313 掲載の参考文献
1) Bang YJ, et al. Lancet. 2010 ; 376 : 687-97.
PubMed
2) Kurokawa Y, et al. Br J Cancer. 2014 ; 110 : 1163-8.
PubMed
3) Miura Y, et al. J Clin Oncol. 2015 ; 33 (suppl 3 ; abstr 126).
 
P.317 掲載の参考文献
1) Hironaka S, et al. J Clin Oncol. 2013 ; 31 : 4438-44.
PubMed
2) Taguchi T, et al. Gan To Kagaku Ryoho. 1998 ; 25 : 1915-24.
PubMed
3) Mai M, et al. Gan To Kagaku Ryoho. 1999 ; 26 : 487-96.
PubMed
4) Shitara K, et al. Lancet Gastroenterol Hepatol. 2017 ; 2 : 277-87.
PubMed
P.320 掲載の参考文献
1) 日本イーライリリー株式会社. サイラムザ適正使用ガイド (治癒切除不能な進行・再発の胃癌). 2016年10月作成.
 
2) Fuchs CS, et al. Lancet. 2014 ; 383 : 31-9.
PubMed
3) Wilke H, et al. Lancet Oncol. 2014 ; 15 : 1224-35.
PubMed
4) 日本胃癌学会. 胃癌治療ガイドライン速報. 2015年10月. http://www.jgca.jp/pdf/ramucirumab20151005.pdf
 
P.323 掲載の参考文献
1) Bando H, et al. Eur J Cancer. 2018 ; 91 : 86-91.
PubMed
2) Wilke H, et al. Lancet Oncol. 2014 ; 15 : 1224-35.
PubMed
P.325 掲載の参考文献
1) Hironaka S, et al. J Clin Oncol. 2014 ; 31 : 4438-44.
 
2) Minami H, et al. Pharmacogenet Genomics. 2007 ; 17 : 497-504.
PubMed
P.328 掲載の参考文献
1) Kang YK, et al. Lancet. 2017 ; 390 : 2461-71.
PubMed
2) Eigentler TK, et al. Cancer Treat Rev. 2016 ; 45 : 7-18.
PubMed
3) Michot JM, et al. Eur J Cancer. 2016 ; 54 : 139-48.
PubMed
4) Puzanov I, et al. J Immunother Cancer. 2017 ; 5 : 95.
 
P.330 掲載の参考文献
1) Sakuramoto S, et al. N Engl J Med. 2007 ; 357 : 1810-20.
PubMed
2) Sasako M, et al. J Clin Oncol. 2011 ; 29 : 4387-93.
PubMed
P.333 掲載の参考文献
1) Bang YJ, et al. Lancet. 2012 ; 379 : 315-21.
PubMed
2) Noh SH, et al. Lancet Oncol. 2014 ; 15 : 1389-96.
PubMed
3) Fuse N, et al. Gastric Cancer. 2017 ; 20 : 332-40.
PubMed

第4章 結腸・直腸癌

P.347 掲載の参考文献
1) Torre LA, Bray F, Siegel RL, et al. Global cancer statistics. 2012. CA Cancer J Clin. 2015 ; 65 : 87-108.
PubMed
2) Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care : a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007 ; 12 : 38-50.
PubMed
3) Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 ; 27 : 663-71.
PubMed
4) Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 ; 360 : 1408-17.
PubMed
5) Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer : results of the randomised phase 3 MRC COIN trial. Lancet. 2011 ; 377 : 2103-14.
PubMed
6) Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study. J Clin Oncol. 2010 ; 28 : 4697-705.
PubMed
7) Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC : phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26 : 2311-9.
PubMed
8) Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010 ; 28 : 4706-13.
PubMed
9) Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO) : a prospectively stratified randomised trial. Lancet Oncol. 2013 ; 14 : 749-59.
 
10) Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 ; 359 : 1757-65.
PubMed
11) Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26 : 1626-34.
PubMed
12) Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 ; 369 : 1023-34.
PubMed
13) Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 ; 33 : 692-700.
PubMed
14) Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis. Eur J Cancer. 2015 ; 51 : 587-94.
PubMed
15) Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 ; 372 : 2509-20.
PubMed
16) Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H) : CheckMate-142 interim results. J Clin Oncol. 2016 ; 34 (suppl ; abstr 3501).
 
17) Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study. J Clin Oncol. 2004 ; 22 : 229-37.
PubMed
18) Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer : the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007 ; 25 : 1670-6.
PubMed
19) Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study. J Clin Oncol. 2008 ; 26 : 2013-9.
PubMed
20) Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016 ; 27 : 1539-46.
PubMed
21) Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 1278-86.
PubMed
22) Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 ; 371 : 1609-18.
PubMed
23) Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT) : a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 ; 15 : 569-79.
PubMed
24) Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 ; 15 : 1065-75.
PubMed
25) Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405 : Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014 ; 32 : 5s (suppl ; abstr LBA3).
 
26) Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wildtype metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017 ; 28 : 1713-29.
PubMed
27) Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 ; 25 : 1539-44.
 
28) Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE) : a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 ; 16 : 499-508.
 
29) Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 ; 381 : 303-12.
 
30) Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 ; 372 : 1909-19.
PubMed
31) Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015 ; 20 : 207-39.
PubMed
32) Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990 ; 322 : 352-8.
PubMed
33) Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon : results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999 ; 17 : 3553-9.
 
34) Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089. J Clin Oncol. 2005 ; 23 : 8671-8.
PubMed
35) Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon : results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 ; 24 : 2059-64.
PubMed
36) Shimada Y, Hamaguchi T, Mizusawa J, et al. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection : final results of JCOG0205. Eur J cancer. 2014 ; 50 : 2231-40.
PubMed
37) Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 ; 352 : 2696-704.
PubMed
38) Yoshida M, Ishiguro M, Ikejiri K, et al. S-1 as adjuvant chemotherapy for stage III colon cancer : a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014 ; 25 : 1743-9.
PubMed
39) Hamaguchi T Shimada Y, Mizusawa J, et al. Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC) : Results of Japan Clinical Oncology Group study (JCOG0910). J Clin Oncol. 2015 ; 33 (suppl ; abstr 3512)
 
40) Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 ; 350 : 2343-51.
PubMed
41) Kuebler JP, Wieand HS, O' Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer : results from NSABP C-07. J Clin Oncol. 2007 ; 25 : 2198-204.
PubMed
42) Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011 ; 29 : 1465-71.
PubMed
43) Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer : results of CALGB 89803. J Clin Oncol. 2007 ; 25 : 3456-61.
 
44) Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer : PETACC-3. J Clin Oncol. 2009 ; 27 : 3117-25.
PubMed
45) Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2+irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009 ; 20 : 674-80.
PubMed
46) Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon : results of NSABP protocol C-08. J Clin Oncol. 2011 ; 29 : 11-6.
PubMed
47) de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT) : a phase 3 randomised controlled trial. Lancet Oncol 2012 ; 13 : 1225-33.
 
48) Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer : a randomized trial. JAMA. 2012 ; 307 : 1383-93.
PubMed
49) Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8) : an open-label, randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 862-73.
 
50) Grothey A, Sobrero A, Meyerhardt JA, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC) : Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy). Ann Oncol. 2017 ; 28 (Suppl 5) : v605-49.
 
51) NCCN. NCCN guildelines Version 2 : Colon Cancer. 2016.
 
52) Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 ; 28 : 3219-26.
PubMed
53) Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer : an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012 ; 18 : 6531-41.
PubMed
54) Yamanaka T, Oki E, Yamazaki K, et al. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone : The SUNRISE Study. J Clin Oncol. 2016 ; 34 : 2906-13.
PubMed
55) Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 ; 351 : 1731-40.
PubMed
56) Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers : results of FFCD 9203. J Clin Oncol. 2006 ; 24 : 4620-5.
 
57) Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer : long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014 ; 15 : 184-90.
PubMed
58) Akasu T, Moriya Y, Ohashi Y, et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy : a multicenter randomized controlled trial. Jpn J Clin Oncol. 2006 ; 36 : 237-44.
PubMed
59) Oki E, Murata A, Yoshida K, et al. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1 : ACTS-RC). Ann Oncol. 2016 ; 27 : 1266-72.
 
60) Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE) : an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 ; 15 : 1245-53.
PubMed
P.357 掲載の参考文献
1) de Gramont A, et al. J Clin Oncol. 2000 ; 18 : 2938-47.
PubMed
2) Goldberg RM, et al. J Clin Oncol, 2004 ; 22 : 23-30.
PubMed
3) Christophe T, et al. J Clin Oncol, 2004 ; 22 : 229-37.
 
4) Kono T, et al. Cancer Chemother Pharmacol. 2013 ; 72 : 1283-90.
PubMed
5) Loprinzi C, et al. J Clin Oncol. 2014 ; 32 : 997-1005.
PubMed
P.360 掲載の参考文献
1) Cassidy J, et al. J Clin Oncol. 2008 ; 26 : 2006-12.
 
2) Rothenberg ML, et al. Ann of Oncol, 2008 ; 19 : 1720-6.
 
3) Doi T, et al. Jpn J Clin Oncol. 2010 ; 40 : 913-20.
PubMed
P.363 掲載の参考文献
1) Douillard JY, et al. Lancet. 2000 ; 355 : 1041-7.
PubMed
2) Tournigand C, et al. J Clin Oncol, 2004 ; 22 : 229-37.
PubMed
3) Grothey A, et al. J Clin Oncol. 2005 ; 23 : 9441-2.
PubMed
P.366 掲載の参考文献
1) Muro K, et al. Lancet Oncol. 2010 ; 11 : 853-60.
PubMed
2) Komatsu Y, et al. Oncology. 2011 ; 80 : 70-5.
 
P.369 掲載の参考文献
1) Falcone A, et al. J Clin Oncol. 2007 ; 25 : 1670-6.
PubMed
P.372 掲載の参考文献
1) Saltz LB, et al. J Clin Oncol. 2008 ; 26 : 2013-9.
PubMed
2) Giantonio BJ, et al. J Clin Oncol. 2007 ; 25 : 1539-44.
PubMed
3) Yamazaki, K et al. Ann Oncol. 2016 ; 27 : 1539-46.
PubMed
4) van Halsema EE, et al. Gastrointest Endosc. 2014 ; 79 : 970-82.e7
 
P.375 掲載の参考文献
1) Saltz LB, et al. J Clin Oncol. 2008 ; 26 : 2013-9.
PubMed
2) J Cassidy, et al. Br J Cancer. 2011 ; 105 : 58-64.
 
3) Sato A, et al. 癌と化療. 2011 ; 38 : 561-9.
 
4) Simkens LH, et al. Lancet. 2015 ; 385 : 1843-52.
PubMed
P.378 掲載の参考文献
1) Yamada Y, et al. Lancet Oncol. 2013 ; 14 : 1278-86.
PubMed
P.381 掲載の参考文献
1) Heinemann V, et al. Lancet Oncol. 2014 ; 15 : 1065-75.
PubMed
2) Yamazaki K, et al. Ann Oncol. 2016 ; 27 : 1539-46.
PubMed
P.383 掲載の参考文献
1) Muro K, et al. Lancet Oncol. 2010 ; 11 : 7853-60.
 
2) Komatsu Y, et al. Acta Oncol. 2012 ; 51 : 867-72.
PubMed
P.386 掲載の参考文献
1) Loupakis F, et al. N Engl J Med. 2014 ; 371 : 1609-18.
PubMed
2) Cremolini C, et al. Lancet Oncol. 2015 ; 16 : 1306-15.
PubMed
P.388 掲載の参考文献
1) Kabbinavar FF, et al. J Clin Oncol. 2005 ; 23 : 3706-12.
PubMed
P.390 掲載の参考文献
1) Tubbutt NC, et al. J Clin Oncol. 2010 ; 28 : 3191-8.
 
2) Cunningham D, et al. Lancet Oncol. 2013 ; 14 : 1077-85.
PubMed
P.392 掲載の参考文献
1) Yoshida M, et al. Eur J Cancer. 2015 ; 51 : 935-41.
PubMed
P.394 掲載の参考文献
1) Nishina T, et al. Clin Colorectal Cancer. 2016 ; 15 : 236-42.
PubMed
P.396 掲載の参考文献
1) Bennouna J, et al. Lancet Oncol, 2013 ; 14 : 29-37.
PubMed
P.399 掲載の参考文献
1) Tabernero J, et al. Lancet Oncol. 2015 ; 16 : 499-508.
 
P.404 掲載の参考文献
1) Van Custem E, et al. J Clin Oncol. 2012 ; 30 : 3499-506.
 
2) Tabernero J, et al. Eur J Cancer. 2014 ; 50 : 320-31.
PubMed
3) Van Cutsem E, et al. Target Oncol. 2016 ; 11 : 383-400.
PubMed
4) Folprecht G, et al. Ann Oncol. 2016 ; 27 : 1273-9.
PubMed
5) Satoh T, et al. J Clin Oncol. 2017 ; 35 (suppl 4 : abstr 707).
 
P.407 掲載の参考文献
1) Bokemeyer C, et al. Eur J Cancer. 2015 ; 51 : 1243-52.
PubMed
2) Lenz HJ, et al. ESMO 2014. abstr 5010.
 
3) Lacouture ME, et al. J Clin Oncol. 2010 ; 28 : 1351-7.
PubMed
P.409 掲載の参考文献
1) Cutsem EV, et al. J Clin Oncol. 2015 ; 33 : 692-700.
 
2) Cutsem EV, et al. N Engl J Med. 2009 ; 360 : 1408-17.
 
P.412 掲載の参考文献
1) Sobrero AF, et al. J Clin Oncol. 2008 ; 26 : 2311-9.
PubMed
2) Cunningham D, et al. N Engl J Med. 2004 ; 351 : 337-45.
 
P.414 掲載の参考文献
1) Jonker DJ, et al. N Engl J Med. 2007 ; 357 : 2040-8.
PubMed
2) Karapetis CS, et al. N Engl J Med. 2008 ; 359 : 1757-65.
PubMed
P.416 掲載の参考文献
1) Douillard JY, et al. N Engl J Med. 2013 ; 369 : 1023-34.
PubMed
2) Schwartzberg LS, et al. J Clin Oncol. 2014 ; 32 : 2240-7.
PubMed
P.418 掲載の参考文献
1) Peeters M, et al. Clin Cancer Res. 2015 ; 21 : 5469-79.
PubMed
P.421 掲載の参考文献
1) Seymour MT, et al. Lancet Oncol. 2013 ; 14 : 749-59.
PubMed
2) Andre T, et al. Ann Oncol. 2013 ; 24 : 412-9.
PubMed
P.423 掲載の参考文献
1) Amado RG, et al. J Clin Oncol. 2008 ; 26 : 1626-34.
PubMed
2) Price TJ, et al. Lancet Oncol. 2014 ; 15 : 569-79.
PubMed
P.425 掲載の参考文献
1) Grothey A, et al. Lancet. 2013 ; 381 : 303-12.
PubMed
2) Yoshino T, et al. Invest New Drugs. 2015 ; 33 : 740-50.
PubMed
P.427 掲載の参考文献
1) Yoshino T, et al. Lancet Oncol. 2012 ; 13 : 993-1001.
PubMed
2) Mayer RJ, et al. N Engl J Med. 2015 ; 372 : 1909-19.
PubMed
P.435 掲載の参考文献
1) Sadahiro S, et al. Ann Oncol. 2015 ; 26 : 2274-80.
PubMed
2) Grothey A, et al. Ann Oncol. 2017 ; 28 (Suppl 5) : v605-49.
 
3) Lembersky BC, et al. J Clin Oncol. 2006 ; 24 : 2059-64.
PubMed
4) Twelves C, et al. N Engl J Med. 2005 ; 352 : 2696-704.
PubMed
5) Shimada Y, et al. Eur J cancer. 2014 ; 50 : 2231-40.
PubMed
6) Yoshida M, et al. Ann Oncol. 2014 ; 25 : 1743-9.
PubMed
7) Hamaguchi T, et al. J Clin Oncol. 2015 ; 33 (suppl ; abstr 3512).
 
8) Murata A, et al. J Clin Oncol. 2015 ; 33 (suppl ; abstr 3515).
 
9) Andre T, et al. N Engl J Med. 2004 ; 350 : 2343-51.
PubMed
10) Haller DG, et al. J Clin Oncol. 2011 ; 29 : 1465-71.
PubMed
11) Andre T, et al. J Clin Oncol. 2015 ; 33 : 4176-87.
PubMed
12) Andre T, et al. J Clin Oncol. 2009 ; 27 : 3109-16.
PubMed

第5章 食道癌

P.450 掲載の参考文献
1) 最新がん統計 http://ganjoho.jp/reg_stat/statistics/stat/summary.html
 
2) Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus : a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992 ; 22 : 172-6.
PubMed
3) Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus : a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001 ; 31 : 419-23.
PubMed
4) Hironaka S, Tsubosa Y, Mizusawa J, et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014 ; 105 : 1189-95.
PubMed
5) Kataoka K, Tsushima T, Mizusawa J, et al. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer : rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). Jpn J Clin Oncol. 2015 ; 45 : 494-8.
PubMed
6) Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004 ; 15 : 955-9.
PubMed
7) Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011 ; 67 : 1265-72.
PubMed
8) Mizota A, Shitara K, Kondo, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology. 2011 ; 81 : 237-42.
PubMed
9) Shirakawa T, Kato K, Nagashima K, et al. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2014 ; 74 : 1207-15.
 
10) Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma : an updated meta-analysis. Lancet Oncol. 2011 ; 12 : 681-92.
PubMed
11) Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 ; 355 : 11-20.
PubMed
12) Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus : a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol. 2003 ; 21 : 4592-6.
 
13) Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012 ; 19 : 68-74.
 
14) Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013 ; 43 : 752-5.
PubMed
15) van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 ; 366 : 2074-84.
 
16) Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 ; 326 : 1593-8.
PubMed
17) Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer : high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 ; 20 : 1167-74.
PubMed
18) Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma : Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009 ; 39 : 638-43.
 
19) Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma : JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011 ; 81 : 684-90.
PubMed
20) Kato K, Nakajima TE, Ito Y, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013 ; 43 : 608-15.
PubMed
21) Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009 ; 137 : 49-54.
PubMed
22) Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus : a Japan Esophageal Oncology Group (JEOG) /Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004 ; 34 : 615-9.
PubMed
23) Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015 ; 106 : 407-12.
PubMed
24) Doi T, Piha-Paul SA, Jalal SI, et al. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. J Clin Oncol. 2018 ; 36 : 61-7.
PubMed
25) Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma : an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017 ; 18 : 631-9.
PubMed
P.457 掲載の参考文献
1) al-Sarraf, et al. J Clin Oncol. 1997 ; 15 : 277-84.
PubMed
2) Minsky BD, et al J Clin Oncol. 2002 ; 20 : 1167-74.
PubMed
3) Kato K, et al. Jpn J Clin Oncol. 2013 ; 43 : 608-15.
PubMed
4) Nakajima TE, et al. Jpn J Clin Oncol. 2009 ; 39 : 37-42.
PubMed
P.461 掲載の参考文献
1) Kato H, et al. Jpn J Clin Oncol. 2009 ; 39 : 638-43.
PubMed
2) Ishida K, et al. Jpn J Clin Oncol. 2004 ; 34 : 615-9.
PubMed
3) Shinoda M, et al. Cancer Sci. 2015 ; 106 : 407-12.
PubMed
P.464 掲載の参考文献
1) Iizuka T, et al. Jpn J Oncol. 1992 ; 22 : 172-6.
 
2) Hayashi K, et al. Jpn J Oncol. 2001 ; 31 : 419-23.
 
3) Ando N, et al. J Clin Oncol. 2003 ; 2 ; 4592-6.
PubMed
4) Ando N, et al. Ann Surg Oncol. 2012 ; 19 : 68-74.
 
P.466 掲載の参考文献
1) Kato K, et al. Esophagus. 2014 ; 11 : 183-8.
 
P.468 掲載の参考文献
1) Muro K, et al. Ann Oncol. 2004 ; 15 : 955-9.
PubMed
2) Taguchi T, et al. Gan To Kagaku Ryoho. 1994 ; 21 : 1997-2005.
PubMed
P.470 掲載の参考文献
1) Kato K, et al. Cancer Chem Pharm. 2011 ; 67 : 1265-72.
 
P.473 掲載の参考文献
1) Hara H, et al. Cancer Sci. 2013 ; 104 : 1455-60.
PubMed
2) Nakamura K, et al. Jpn J Clin Oncol 2013 ; 43 : 752-5.
PubMed
P.476 掲載の参考文献
1) Hironaka S, et al. Cancer Sci. 2014 ; 105 : 1189-95.
PubMed
2) Kataoka K, et al. Jpn J Clin Oncol. 2015 ; 45 : 494-8.
PubMed

第6章 肝細胞癌 / 胆道癌 / 膵癌

P.488 掲載の参考文献
1) Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma : A randomized phase II trial. J Clin Oncol. 2015 ; 33 (suppl ; abstr 4076).
 
2) Kudo M, Ueshima K, Yokosuka O, et al. Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. J Hepatol. 2016 ; 64 (suppl ; abstr LBO4) : S209-S210.
 
3) Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 ; 359 : 378-90.
PubMed
4) Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 ; 10 : 25-34.
 
5) Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008 ; 99 : 159-65.
PubMed
6) Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 ; 389 : 56-66.
PubMed
7) Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 ; 362 : 1273-81.
PubMed
8) Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer. 2010 ; 103 : 469-74.
PubMed
9) Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013 ; 104 : 1211-6.
 
10) Kanai M, Hatano E, Kobayashi S, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol. 2015 ; 75 : 293-300.
 
11) Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol. 1997 ; 15 : 2403-13.
 
12) Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 ; 25 : 1960-6.
 
13) Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST Study. J Clin Oncol. 2013 ; 31 : 1640-8.
PubMed
14) Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 ; 364 : 1817-25.
PubMed
15) Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 ; 369 : 1691-703.
PubMed
16) Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for metastatic chemotherapy-naive Japanese pancreatic cancer patients. Cancer Sci. 2014 ; 105 : 1321-6.
PubMed
17) Ueno H, Ikeda M, Ueno M, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016 ; 77 : 595-603.
PubMed
18) Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib : the LAP07 randomized clinical trial. JAMA. 2016 ; 315 : 1844-53.
PubMed
19) Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA. 2007 ; 297 : 267-77.
PubMed
20) Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009 ; 101 : 908-15.
 
21) Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016 ; 388 : 248-57.
PubMed
P.492 掲載の参考文献
1) Okusaka T, et al. Invest New Drugs. 2012 ; 30 : 2015-25.
PubMed
2) Kora S, et al. Cardiovasc Intervent Radiol. 2013 ; 36 : 1023-9.
PubMed
3) 奥坂拓志, ほか. 肝臓. 2015 ; 56 Suppl 1 ; A371.
 
P.495 掲載の参考文献
1) Yoshikawa M, et al. Hepatology Res. 2008 ; 38 : 474-83.
 
2) Ikeda M, et al. Cancer Chemother Pharmacol. 2013 ; 72 : 463-70.
PubMed
P.497 掲載の参考文献
1) Llovet, et al. N Engl J Med. 2008 ; 359 : 378-90.
PubMed
2) Furuse, J et al. Cancer Sci. 2008 ; 99 : 159-65.
PubMed
3) Kaneko, S et al. J Gastroenterol. 2016 ; 51 : 1011-21.
 
P.500 掲載の参考文献
1) Wilhelm SM, et al. Int J Cancer. 2011 ; 129 : 245-55.
PubMed
2) Bruix J, et al. Lancet. 2017 ; 389 : 56-66.
PubMed
P.503 掲載の参考文献
1) Valle J, et al. N Engl J Med. 2010 ; 362 : 1273-81.
 
2) Okusaka T, et al. Br J Cancer. 2010 ; 103 : 469-74.
PubMed
3) Stewart DJ, et al. Cancer Chemotherapy Pharmacol. 1997 ; 40 : 293-308.
 
P.505 掲載の参考文献
1) Okusaka T, et al. Cancer Chemother Pharmacol. 2006 ; 57 : 647-53.
PubMed
P.510 掲載の参考文献
1) Furuse J, et al. Cancer Chemother Pharmacol. 2008 ; 62 : 849-55.
PubMed
2) Morizane C, et al. Cancer Sci. 2013 ; 104 : 1211-6.
PubMed
3) Mizusawa J, et al. Jpn J Clin Oncol. 2016 ; 46 : 385-8.
PubMed
4) Kanai M, et al. Cancer Chemother Pharmacol. 2015 ; 75 : 293-300.
PubMed
5) Ioka T, et al. J Clin Oncol. 2015 ; 33 (suppl ; abstr TPS4141).
 
P.513 掲載の参考文献
1) Burris HA, 3rd, et al. J Clin Oncol. 1997 ; 15 : 2403-13.
PubMed
2) Okada S, et al. Jpn J Clin Oncol. 2001 ; 31 : 7-12.
 
3) Ueno H, et al. J Clin Oncol. 2013 ; 31 : 1640-8.
PubMed
P.516 掲載の参考文献
1) Von Hoff DD, et al. N Engl J Med. 2013 ; 369 : 1691-703.
PubMed
2) Ueno H, et al. Cancer Chemother Pharmacol. 2016 ; 77 : 595-603.
PubMed
P.520 掲載の参考文献
1) Okusaka T, et al. Cancer Chemother Pharmacol. 2008 ; 61 : 615-21.
PubMed
2) Ueno H, et al. J Clin Oncol. 2013 ; 31 : 1640-8.
PubMed
3) Morizane C, et al. Cancer Chemother Pharmacol. 2009 ; 63 : 313-9.
PubMed
4) Uesaka K, et al. Lancet. 2016 ; 388 : 248-57.
PubMed
5) 大鵬薬品工業株式会社. テガフール・ギメラシル・オテラシルカリウム配合カプセル剤・顆粒剤添付文書.
 
P.523 掲載の参考文献
1) Moore MJ, et al. J Clin Oncol. 2007 ; 25 : 1960-6.
PubMed
2) Okusaka T, et al. Cancer Sci. 2011 ; 102 : 425-31.
PubMed
3) Hammel P, et al. JAMA. 2016 ; 315 : 1844-53.
PubMed
P.527 掲載の参考文献
1) Conroy T, et al. N Engl J Med. 2011 ; 364 : 1817-25.
PubMed
2) Okusaka T, et al. Cancer Sci. 2014 ; 105 : 1321-6.
PubMed
3) Stein SM, et al. Br J Cancer. 2016 ; 114 : 809-12.
 
4) Ueno M, et al. J Clin Oncol. 2016 ; 34(suppl ; abstr 4111).
 

第7章 婦人科癌

P.542 掲載の参考文献
1) 日本婦人科腫瘍学会編. 卵巣がん治療ガイドライン 2015年版. 東京 : 金原出版 ; 2015.
 
2) 日本婦人科腫瘍学会編. 子宮頸癌治療ガイドライン 2011年版. 東京 : 金原出版 ; 2011.
 
3) 日本婦人科腫瘍学会編. 子宮体がん治療ガイドライン 2013年版. 東京 : 金原出版 ; 2013.
 
4) Du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 ; 95 : 1320-9.
 
5) Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised controlled trial. Lancet. 2009 ; 374 : 1331-8.
PubMed
6) Van Der Burg ME, Van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995 ; 332 : 629-34.
PubMed
7) Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer : the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 ; 361 : 2099-2106.
PubMed
8) Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008 ; 99 : 653-8.
PubMed
9) Sugiyama T, Okamoto A, Enomoto T, et al. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma : JGOG3017/GCIG Trial. J Clin Oncol. 2016 ; 34 : 2881-7.
 
10) Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix : a systematic review and meta-analysis. Lancet. 2001 ; 358 : 781-6.
PubMed
11) Shimada M, Sato S, Oishi T, et al. Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer. Int J Clin Oncol. 2016 ; 21 : 969-74.
PubMed
12) Monk BJ, Sill MW, Mcmeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma : a Gynecologic Oncology Group study. J Clin Oncol. 2009 ; 27 : 4649-55.
PubMed
13) Tewari KS, Sill MW, Long HJ, 3rd et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 ; 370 : 734-43.
PubMed
14) Sato S, Shimada M, Ohta T, et al. Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy. Int J Gynecol Cancer. 2016 ; 26 : 561-7.
PubMed
15) Johnson N, Bryant A, Miles T. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. 2011 ; 10 : CD003175.
PubMed
16) Eto T, Saito T, Shimokawa M, et al. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy : a retrospective multi-institutional study of 426 patients in Japan. Gynecol Oncol. 2013 ; 131 : 574-80.
PubMed
17) Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma : a gynecologic oncology group study. J Clin Oncol. 2004 ; 22 : 3902-8.
PubMed
18) Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma : a Gynecologic Oncology Group Study. J Clin Oncol. 2004 ; 22 : 2159-66.
PubMed
P.548 掲載の参考文献
1) Ozols RF, et al. J Clin Oncol. 2003 ; 21 : 3194-200.
PubMed
2) Katsumata N, et al. Lancet. 2009 ; 374 : 1331-8.
PubMed
3) Katsumata N, et al. Lancet Oncol. 2013 ; 10 : 1020-6.
PubMed
4) Chan JK, et al. N Eng J Med. 2016 ; 374 : 738-48.
 
P.551 掲載の参考文献
1) Vasey PA, et al. J Natl Cancer Inst. 2004 ; 96 : 1682-91.
PubMed
2) Mori J, et al. Int J Clin Oncol. 2007 ; 12 : 205-11.
 
P.555 掲載の参考文献
1) Burger RA, et al. N Eng J Med. 2011 ; 365 : 2473-83.
 
2) Oza AM, et al. Lancet Oncol. 2015 ; 26 : 928-36.
PubMed
3) Burger RA, et al. J Clin Oncol. 2014 ; 32 : 1210-7.
PubMed
P.558 掲載の参考文献
1) Pignata S, et al. J Clin Oncol. 2011 ; 29 : 3628-35.
PubMed
2) Pujade-Lauraine E, et al. J Clin Oncol. 2010 ; 28 : 3323-9.
PubMed
3) Wagner U, et al. Br J Cancer. 2012 ; 107 : 588-91.
PubMed
P.561 掲載の参考文献
1) Pfisterer J, et al. J Clin Oncol. 2006 ; 24 : 4699-707.
PubMed
2) Aghajanian C, et al. J Clin Oncol. 2012 ; 30 : 2039-45.
PubMed
P.564 掲載の参考文献
1) Sugiyama T, et al. Oncology. 2002 ; 63 : 16-22.
PubMed
2) Sugiyama T, et al. Cancer Lett. 1998 ; 128 : 211-8.
PubMed
3) Sugiyama T, et al. J Clin Oncol. 2016 ; 34 : 2881-7.
PubMed
4) Benson AB, et al. J Clin Oncol. 2004 ; 22 : 2918-26.
PubMed
P.567 掲載の参考文献
1) Pujade-Lauraine E, et al. Lancet Oncol. 2017 ; 18 : 1274-84.
PubMed
2) Cancer Genome Atlas Research Network. Nature. 2011 ; 474 : 609-15.
 
P.570 掲載の参考文献
1) Gordon AN, et al. J Clin Oncol. 2001 ; 19 : 3312-22.
 
2) Ferrandina G, et al. J Clin Oncol. 2008 ; 26 : 890-6.
PubMed
3) Katsumata N, et al. Jpn J Clin Oncol. 2008 ; 38 : 777-85.
PubMed
4) 島田宗明, 他. 日産婦会誌. 2011 ; 63 : 868.
 
P.573 掲載の参考文献
1) Ten Bokkel Huinink W, et al. Ann Oncol. 2004 ; 15 : 100-3.
PubMed
2) Markman M, et al. J Clin Oncol. 2002 ; 20 : 2365-9.
 
3) Kita T, et al. Gynecol Oncol. 2004 ; 92 : 813-8.
PubMed
P.575 掲載の参考文献
1) Watanabe Y, et al. Int J Clin Oncol. 2008 ; 13 : 345-8.
PubMed
2) D'Agostino G, et al. Gynecol Oncol. 2003 ; 88 : 266-9.
PubMed
3) Ferrandina G, at al. J Clin Oncol. 2008 ; 26 : 890-6.
 
4) Mutch DG, et al. J Clin Oncol. 2007 ; 25 : 2811-8.
PubMed
P.577 掲載の参考文献
1) Matsumoto K, et al. Gynecol Oncol. 2006 ; 100 : 412-6.
PubMed
2) Minami H, et al. Pharmacogenetics and Genomics. 2007 ; 17 : 497-504.
PubMed
P.580 掲載の参考文献
1) Kudelka AP, et al. J Clin Oncol. 1996 ; 14 : 1552-7.
PubMed
2) Ten Bokkel Huinink W, et al. Ann Oncol. 2004 ; 15 : 100-3.
PubMed
3) Gordon AN, et al. J Clin Oncol. 2001 ; 19 : 3312-22.
 
4) Sehouli J, et al. J Clin Oncol. 2011 ; 29 : 242-8.
PubMed
P.583 掲載の参考文献
1) Moore DH, et al. J Clin Oncol. 2004 ; 22 : 3113-9.
PubMed
2) Monk BJ, et al. J Clin Oncol. 2009 ; 27 : 4649-55.
PubMed
3) Tewari KS, et al. N Engl J Med. 2014 ; 370 : 734-43.
PubMed
P.586 掲載の参考文献
1) Tewari KS, et al. N Engl J Med. 2014 ; 370 : 734-43.
PubMed
P.588 掲載の参考文献
1) Kitagawa R, et al. J Clin Oncol. 2015 ; 33 : 2129-35.
PubMed
P.591 掲載の参考文献
1) Eifel PJ, et al. J Clin Oncol. 2004 ; 22 : 872-80.
PubMed
2) Whitney CW, et al. J Clin Oncol. 1999 ; 17 : 1339-48.
PubMed
3) Morris M, et al. N Engl J Med. 1999 ; 340 : 1137-43.
 
4) Toita T, et al. Gynecol Oncol. 2012 ; 126 : 211-6.
PubMed
5) Rose PG, et al. N Engl J Med. 1999 ; 340 : 1144-53.
PubMed
6) 日本婦人科腫瘍学会 (編). 子宮頚癌治療ガイドライン 2011年版. 東京 : 金原出版 ; 2011.
 
7) 日本癌治療学会 (編). 制吐薬適正使用ガイドライン 2014年6月 ver 1.2
 
P.594 掲載の参考文献
1) Sugiyama T, et al. Oncology. 2000 ; 58 : 31-7.
PubMed
2) Sugiyama T, et al. Br J Cancer. 1999 ; 23 : 95-8.
PubMed
3) Shoji T, et al. Int J Clin Oncol. 2016 ; 21 : 1120-7.
PubMed
4) 日本癌治療学会 (編). G-CSF適正使用ガイドライン 2013年版 ver. 3
 
5) 日本癌治療学会 (編). 制吐薬適正使用ガイドライン 2014年6月 ver. 1.2
 
P.597 掲載の参考文献
1) Long HJ 3rd, et al. J Clin Oncol. 2005 ; 23 : 4626-33.
PubMed
2) Monk BJ, et al. J Clin Oncol. 2009 ; 27 : 4649-55.
PubMed
3) 日本癌治療学会 (編). G-CSF適正使用ガイドライン 2013年版 ver. 3
 
P.600 掲載の参考文献
1) Randall ME, et al. J Clin Oncol. 2006 ; 24 : 36-44.
PubMed
2) Aapro MS, et al. Ann Oncol. 2003 ; 14 : 441-8.
PubMed
3) Trope C, et al. Am J Obstet Gynecol. 1984 ; 149 : 379-81.
PubMed
4) 日本婦人科腫瘍学会. 子宮体がん治療ガイドライン 2013年版 第3版. 東京 : 金原出版 ; 2013.
 
5) Go RS, et al. J Clin Oncol. 1999 ; 17 : 409-22.
PubMed
6) Fleming GF, et al. J Clin Oncol. 2004 ; 22 : 2159-66.
PubMed
P.603 掲載の参考文献
1) Michener cm, et al. J Cancer Res Clin Oncol. 2005 ; 131 : 581-4.
PubMed
2) Akram T, et al. Am J Oncol. 2005 ; 192 : 1365-7.
 
3) Hoskins PJ, et al. J Clin Oncol. 2001 ; 19 : 4048-53.
 
4) Nomura H, et al. Ann Oncol. 2011 ; 22 : 636-42.
PubMed
5) Miller D, et al. Gynecol Oncol. 2012 ; 125 : 771-3.
 
P.606 掲載の参考文献
1) Gordon AN, et al. Ann Oncology. 2002 ; 13 (suppl 5) : 109.
 
2) Nomura H, et al. Ann Oncol. 2011 ; 22 : 636-42.
PubMed
3) Vasey P, Scottish Gynecologic Cancer Trials Group. Proc Am Soc Clin Oncol. 2001 ; 20 : 202a.
 
P.609 掲載の参考文献
1) van der Graaf WT et al. Lancet. 2012 ; 379 : 1879-86.
PubMed
2) Kawai A et al. Jpn J Clin Oncol. 2016 ; 46 : 248-53.
PubMed
3) MASCC/ESMO Antiemetic Guidelines 2016. www.mascc.org
 
P.612 掲載の参考文献
1) Demetri GD, et al. J Clin Oncol. 2016 ; 34 : 786-93.
PubMed
2) Kawai A, et al. Lancet Oncol. 2015 ; 16 : 406-16.
PubMed
3) Twelves C, et al. Eur J Cancer. 2003 ; 39 : 1842-51.
PubMed
P.615 掲載の参考文献
1) Schoffski P, et al. Lancet. 2016 ; 387 : 1629-37.
PubMed
2) Naito Y, et al. J Clin Oncol. 2014 ; 32 : 5s (suppl ; abstr 10567).
 
3) NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines(R)) Antiemesis Version I. 2014. www.nccn.com
 

第8章 泌尿器癌

P.631 掲載の参考文献
1) Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985 ; 133 : 403-407.
PubMed
2) von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase 3 study. J Clin Oncol. 2000 ; 18 : 3068-3077.
PubMed
3) Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer : long-term results in 1,054 patients. J Clin Oncol. 2001 ; 19 : 666-675.
 
4) Natale RB, Grossman HB, Blumenstein B, et al. SWOG 8710 (INT-0080) : randomized phase 3 trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. Proc Natl Acad Sci USA. 2001 ; 20 : 2a.
 
5) Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer : literature review. Eur Urol. 2005 ; 48 : 60-67.
PubMed
6) Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 ; 351 : 1513-1520.
PubMed
7) Tannock IF, de Wit R, Berry WR, et al : TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 ; 351 : 1502-1512.
PubMed
8) National Comprehensive Cancer Network,Clinical Practice Guidelines In Oncology-V.1.2004
 
9) Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 ; 337 : 295-300.
PubMed
10) Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer : an overview of the randomised trials. Lancet. 2000 ; 355 : 1491-1498.
 
11) Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2 b compared with interferon alfa-2 b alone for metastatic renal-cell cancer. N Engl J Med. 2001 ; 345 : 1655-1659.
PubMed
12) Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 ; 17 : 2530-2540.
PubMed
13) Hudes G, Carducci M, Tomczak P, et al : Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 2271-2281.
PubMed
14) Escudier B, Eisen T, Stadler WM, et al : TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 125-134.
 
15) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 115-124.
PubMed
16) Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma ; a double blind randomized, placebo controlled phase III trial. Lancet, 2008 ; 372 : 449-456.
PubMed
17) Motzer RJ, Nichols CJ, Margolin KA, et al. Phase 3 randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor prognosis metastatic germ cell tumors. J Clin Oncol. 2007 ; 25 : 247-256.
PubMed
18) Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007 ; 357 : 340-348.
PubMed
19) Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol. 1997 ; 15 : 2553-2558.
PubMed
P.636 掲載の参考文献
1) Loehrer PJ, et al. J Clin Oncol. 1992 ; 10 : 1066-73.
PubMed
2) 日本泌尿器科学会. M-VAC療法適正使用情報. 2004 ; 1-15.
 
3) Grossman HB, et al. N Engl J Med. 2003 ; 349 : 859-66.
PubMed
4) Kitamura H, et al. Annals of Oncology. 2014 ; 25 : 1192-8.
PubMed
5) Sterngberg CN, et al. J Clin Oncol. 2001 ; 19 : 2638-46.
 
P.639 掲載の参考文献
1) von der Maase H, et al. J Clin Oncol. 2000 ; 17 : 3068-77.
PubMed
2) Sternberg CN, et al. Lancet Oncol. 2015 ; 16 : 76-86.
PubMed
P.642 掲載の参考文献
1) NCCN Guidelines(R). 2016 ver2
 
2) EAU Guidelines. 2016
 
P.645 掲載の参考文献
1) Klotz L, et al. BJU Int. 2008 ; 102 : 1531-8.
PubMed
2) Akaza H, et al. Cancer. 2009 ; 115 : 3437-45.
PubMed
P.647 掲載の参考文献
1) Scher HI, et al. N Engl J Med. 2012 ; 367 : 1187-97.
PubMed
2) Beer TM, et al. N Engl J Med. 2014 ; 371 : 424-33.
PubMed
3) Akaza H, et al. Int J clin Oncol. 2016 ; 21 : 773-82.
PubMed
P.650 掲載の参考文献
1) de Bono JS, et al. N Engl J Med. 2011 ; 364 : 1995-2005.
PubMed
2) Ryan CJ, et al. N Engl J Med. 2013 ; 371 : 138-48.
 
3) Satoh T, et al. Jpn J clin Oncol. 2014 ; 44 : 1206-15.
PubMed
4) Matusbara N, et al. Jpn J clin Oncol. 2014 ; 44 : 1216-26.
 
P.653 掲載の参考文献
1) Tannock IF, et al. N Engl J Med. 2004 ; 351 : 1502-12.
PubMed
2) Petrylak DP, et al. N Engl J Med. 2004 ; 351 : 1513-20.
PubMed
3) Naito S, et al. Jpn J Clin Oncol. 2008 ; 38 : 365-72.
PubMed
P.655 掲載の参考文献
1) de Bono JS, et al. Lancet. 2010 ; 376 : 1147-54.
PubMed
2) Nozawa M, et al. Int J clin Oncol. 2015 ; 20 : 1026-34.
PubMed
P.657 掲載の参考文献
1) Parker C, et al. N Engl J Med. 2013 ; 369 : 213-23.
 
P.659 掲載の参考文献
1) Motzer RJ, et al. N Engl J Med. 2013 ; 369 : 722-31.
PubMed
2) Pyrhonen S, et al. J Clin Oncol. 1999 ; 17 : 2859-67.
PubMed
P.661 掲載の参考文献
1) Escudier, et al. N Engl J Med. 2007 ; 356 : 125-34.
PubMed
2) Escudier, et al. J Clin Oncol. 2009 ; 27 : 1280-9.
 
3) ネクサバール(R) 錠 200 mg (一般名 : ソラフェニブトシル酸塩錠) 特定使用成績調査 最終報告書 (腎機能の追加解析を含む) (根治切除不能又は転移性の腎細胞癌). 2015. 4.
 
P.663 掲載の参考文献
1) Motzer RJ, et al. N Engl J Med. 2007 ; 356 : 115-24.
PubMed
2) Motzer RJ, et al. J Clin Oncol. 2009 ; 27 : 3584-90.
PubMed
3) Motzer RJ, et al. JAMA. 2006 ; 295 : 2516-24.
PubMed
4) スーテント(R) カプセル12.5 mg 特定使用成績調査 最終報告書. 2012. 3.
 
P.665 掲載の参考文献
1) Motzer RJ, et al. Lancet. 2008 ; 372 : 449-56.
PubMed
2) Motzer RJ, et al. N Engl J Med. 2015 ; 373 : 1803-13.
PubMed
3) アフィニトール(R) 錠2.5 mg, 5 mg (根治切除不能又は転移性の腎細胞癌) 特定使用成績調査. 2016. 3.
 
P.667 掲載の参考文献
1) Hudes G, et al. N Engl J Med. 2007 ; 356 : 2271-81.
PubMed
2) トーリセル点滴静注液25 mg副作用発現状況一覧. 2016. 10.
 
P.669 掲載の参考文献
1) Motzer RJ, et al. Lancet Oncol. 2013 ; 14 : 1287-94.
 
2) Motzer RJ, et al. J Clin Oncol. 2009 ; 27 : 3584-90.
PubMed
3) インライタ(R) 錠 使用成績調査 (安全性) 2016.
 
P.671 掲載の参考文献
1) Motzer RJ, et al. N Engl J Med. 2013 ; 369 : 722-31.
PubMed
2) Motzer RJ, et al. N Engl J Med. 2014 ; 370 : 1769-70.
PubMed
3) Sternberg CN, et al. J Clin Oncol. 2010 ; 28 : 1061-8.
PubMed
P.673 掲載の参考文献
1) Motzer RJ, et al. N Engl J Med. 2015 ; 373 : 1803-13.
PubMed
P.675 掲載の参考文献
1) Culine S, et al. Ann Oncol. 2007 ; 18 : 917-24.
PubMed
2) Loehrer PJ, et al. J Clin Oncol. 1995 ; 13 : 470-6.
PubMed
P.678 掲載の参考文献
1) Shintaku I, et al. Jpn J Clin Oncol. 2008 ; 38 : 281-7.
PubMed
2) Loehrer PJ, et al. J Clin Oncol. 1995 ; 13 : 470-6.
PubMed
3) Culine S, et al. Ann Oncol. 2007 ; 18 : 917-24.
PubMed
P.681 掲載の参考文献
1) Nichols CR, et al. J Clin Oncol. 1998 ; 16 : 1287-93.
PubMed
2) Motzer RJ, et al. Cancer. 1990 ; 66 : 2476-81.
PubMed
3) Loehrer PJ Sr, et al. J Clin Oncol. 1998 ; 16 : 2500-4.
PubMed
P.684 掲載の参考文献
1) Motzer RJ, et al. J Clin Oncol. 2000 ; 18 : 2413-8.
PubMed
2) Kondagunta GV, et al. J Clin Oncol. 2005 ; 23 : 6549-55.
PubMed
3) Kawai K, et al. Jpn J Clin Oncol. 2003 ; 33 : 127-31.
PubMed

第9章 頭頸部癌

P.698 掲載の参考文献
1) Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 ; 349 : 2091-8.
PubMed
2) Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11 : a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 ; 31 : 845-52.
PubMed
3) Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 ; 101 : 498-506.
 
4) Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma : three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000 ; 355 : 949-55.
 
5) Browman GP, Hodson DI, Mackenzie RJ, et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer : A systematic review of the published literature with subgroup analysis. Head Neck. 2001 ; 23 : 579-89.
PubMed
6) Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 ; 354 : 567-78.
PubMed
7) Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 ; 357 : 1695-704.
PubMed
8) Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 ; 357 : 1705-15.
PubMed
9) Cohen EE, Karrison TG, Kocherginsky, M et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 ; 32 : 2735-43.
PubMed
10) Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM) : a randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 257-64.
PubMed
11) Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 ; 25 : 216-25.
PubMed
12) Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study. J Clin Oncol. 2014 ; 32 (suppl ; abstr 6004)
 
13) Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 ; 350 : 1945-52.
PubMed
14) Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 ; 350 : 1937-44.
PubMed
15) Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers : A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005 ; 27 : 843-50.
PubMed
16) Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma : phase III randomized trial. J Natl Cancer Inst. 2011 ; 103 : 1761-70.
 
17) Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 ; 359 : 1116-27.
PubMed
18) Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 ; 375 : 1856-67.
PubMed
19) Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer : a randomised, double-blind, phase 3 trial. Lancet. 2014 ; 384 : 319-28.
PubMed
20) Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 ; 372 : 621-30.
PubMed
21) Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol. 2017 ; 7 : 25.
PubMed
22) Wells SA, Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer : a randomized, double-blind phase III trial. J Clin Oncol. 2012 ; 30 : 134-41.
PubMed
P.703 掲載の参考文献
1) Forastiere AA, et al. N Engl J Med. 2003 ; 349 : 2091-8.
PubMed
2) Adelstein DJ, et al. J Clin Oncol. 2003 ; 21 : 92-8.
PubMed
3) Bernier J, et al. Head Neck. 2005 ; 27 : 843-50.
PubMed
P.706 掲載の参考文献
1) Pignon JP, et al. Radiother Oncol. 2009 ; 92 : 4-14.
PubMed
2) Pointreau Y, et al. J Natl Cancer Inst. 2009 ; 101 : 498-506.
PubMed
3) Vermorken JB, et al. N Eng J Med. 2007 ; 357 : 1695-1704.
 
P.709 掲載の参考文献
1) Vermorken JB, et al. N Engl J Med. 2008 ; 359 : 1116-27.
PubMed
2) Yoshino T, et al. Jpn J Clin Oncol. 2013 ; 43 : 524-31.
PubMed
3) 日本癌治療学会 (編). 制吐薬適正使用ガイドライン 2015年10月 第2版. 東京 : 金原出版 ; 2015.
 
4) Antiemesis. NCCN Guidelines. ver 2. 2016
 
P.712 掲載の参考文献
1) Ferris RL, et al. N Engl J Med. 2016 ; 375 : 1856-67.
PubMed
2) Kiyota N, et al. Oral Oncol. 2017 ; 73 : 138-46.
PubMed
P.715 掲載の参考文献
1) Hitt R, et al. Ann Oncol. 2012 ; 23 : 1016-22.
PubMed
2) Jimenez B, et al. Oral Oncol. 2013 ; 49 : 182-5.
PubMed
3) Sosa AE, et al. Eur Arch Otorhinolaryngol. 2014 ; 271 : 373-8.
PubMed
4) Peron J, et al. Anticancer Drugs. 2012 ; 23 : 996-1001.
PubMed
P.718 掲載の参考文献
1) Bonner JA, et al. N Engl J Med. 2006 ; 354 : 567-78.
PubMed
2) Bonner JA, et al. Lancet Oncol. 2010 ; 11 : 21-8.
PubMed
3) Okano S, et al. Jpn J Clin Oncol. 2013 ; 43 : 476-82.
PubMed
4) David IR, et al. J Clin Oncol. 2016 ; 34 : 1300-8.
 
P.720 掲載の参考文献
1) Tahara M, et al. Ann Oncol. 2018 ; 29 : 1004-9.
PubMed
P.723 掲載の参考文献
1) Brose MS, et al. Lancet. 2014 ; 384 : 319-28.
PubMed
2) Tahara M, et al. 日本内分泌・甲状腺外科学会雑誌. 2014 ; 31 (Suppl.1) : S80.
 
3) ネクサバール(R) 添付文書
 
P.726 掲載の参考文献
1) Schlumberger M, et al. N Engl J Med. 2015 ; 12 : 372 : 621-30.
PubMed
2) Kiyota N, et al. Cancer Sci. 2015 ; 106 : 1714-21.
PubMed
P.729 掲載の参考文献
1) Wells SA, et al. J Clin Oncol. 2012 ; 30 : 134-41.
PubMed
2) カプレルサ錠 100 mg 医薬品インタビューフォーム 第4版
 
3) カプレルサ錠 100 mg 添付文書
 

第10章 整形外科腫瘍

P.746 掲載の参考文献
1) Ogura K, Higashi T, Kawai A. Statistics of bone sarcoma in Japan : Report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci. 2017 ; 22 : 133-43.
PubMed
2) Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma : results from pre-randomisation treatment. Ann Oncol. 2015 ; 26 : 407-14.
PubMed
3) Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP : First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol. 2015 ; 33 : 2279-87.
PubMed
4) Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1) : an open-label, international, randomised controlled trial. Lancet Oncol. 2016 ; 17 : 1396-408.
PubMed
5) Iwata S, Yonemoto T, Iizasa T, et al. Oligo-Recurrence of Osteosarcoma Patients : Treatment Strategies for Pulmonary Metastases. Ann Surg Oncol. 2015 ; 22 (Suppl 3) : S1332-8.
 
6) Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 ; 348 : 694-701.
 
7) Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors : a Children's Oncology Group Study. J Clin Oncol. 2009 ; 27 : 2536-41.
 
8) Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012 ; 30 : 914-20.
PubMed
9) Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults : meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997 ; 350 : 1647-54.
PubMed
10) Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008 ; 113 : 573-81.
PubMed
11) Tanaka K, Mizusawa J, Fukuda H, et al. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol. 2015 ; 45 : 555-61.
PubMed
12) Kataoka K, Tanaka K, Mizusawa J, et al. A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma : Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol. 2014 ; 44 : 765-9.
 
13) Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma : a randomised controlled phase 3 trial. Lancet Oncol. 2014 ; 15 : 415-23.
PubMed
14) Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma : results of a phase II trial. J Clin Oncol. 2002 ; 20 : 2824-31.
PubMed
15) Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas : results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007 ; 25 : 2755-63.
PubMed
16) Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma : a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009 ; 27 : 3126-32.
PubMed
17) Nakamura T, Matsumine A, Kawai A, et al. Cancer. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma : A Japanese Musculoskeletal Oncology Group (JMOG) study. 2016 ; 122 : 1408-16.
PubMed
18) Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 ; 34 : 786-93.
 
19) Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma : a randomised, open-label, phase 2 study. Lancet Oncol. 2015 ; 16 : 406-16.
PubMed
20) Schoffski P, Ray-Coquard IL, CioffiA, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma : a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 ; 12 : 1045-52.
PubMed
21) Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 ; 387 : 1629-37.
 
22) Kawai A, Araki N, Naito Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017 ; 47 : 137-44.
PubMed
23) 日本整形外科学会 (監修). 軟部腫瘍診療ガイドライン改訂第2版 2012. 東京 : 南江堂 ; 2012.
 
P.752 掲載の参考文献
1) Souhami RL, et al. Lancet. 1997 ; 350 : 911-7.
PubMed
2) Bielack SS, et al. J Clin Oncol. 2015 ; 33 : 2279-87.
PubMed
3) Marina NM, et al. Lancet Oncol. 2016 ; 17 : 1396-408.
PubMed
4) Iwamoto Y, et al. J Orthop Sci. 2009 ; 14 : 397-404.
PubMed
P.755 掲載の参考文献
1) Jaffe N. Cancer. 1972 ; 30 : 1627-31.
PubMed
2) Bielack SS, et al. J Clin Oncol. 2015 ; 33 : 2279-87.
PubMed
3) Marina NM, et al. Lancet Oncol. 2016 ; 17 : 1396-408.
PubMed
4) Iwamoto Y, et al. J Orthop Sci. 2009 ; 14 : 397-404.
PubMed
P.758 掲載の参考文献
1) Marti C, et al. Cancer Treat Rep. 1985 ; 69 : 115-7.
PubMed
2) Iwamoto Y, et al. J Orthop Sci. 2009 ; 14 : 397-404.
PubMed
3) Marina NM, et al. Lancet Oncol. 2016 ; 17 : 1396-1408.
PubMed
P.761 掲載の参考文献
1) Judson I, et al. Lancet Oncol. 2014 ; 15 : 415-23.
PubMed
2) Tap WD, et al. Lancet. 2016 ; 388 : 488-97.
PubMed
P.764 掲載の参考文献
1) Tanaka K, et al. Jpn J Clin Oncol. 2015 ; 45 : 555-61.
PubMed
2) Kataoka K, et al. Jpn J Clin Oncol. 2014 ; 44 : 765-9.
PubMed
3) Judson I, et al. Lancet Oncol. 2014 ; 15 : 415-23.
PubMed
P.767 掲載の参考文献
1) Miser JS, et al. J Clin Oncol. 1987 ; 5 : 1191-8.
PubMed
2) Saeter G, et al. Eur J Cancer. 1997 ; 33 : 1551-8.
PubMed
3) Edmonson JH, et al. J Natl Cancer Inst. 1989 ; 81 : 863-6.
PubMed
P.769 掲載の参考文献
1) Sleijfer S, et al. J Clin Oncol. 2009 ; 27 : 3126-32.
PubMed
2) van der Graaf WT, et al. Lancet. 2012 ; 379 : 1879-86.
PubMed
3) Nakamura T, et al. Cancer. 2016 ; 122 : 1408-16.
PubMed
P.772 掲載の参考文献
1) Demetri GD, et al. J Clin Oncol. 2016 ; 34 : 786-93.
PubMed
2) Ueda T, et al. Invest New Drugs. 2014 ; 32 : 691-9.
PubMed
3) Kawai A, et al. Lancet Oncol. 2015 ; 16 : 406-16.
PubMed
P.774 掲載の参考文献
1) Schoffski P, et al. Lancet Oncol. 2011 ; 12 : 1045-52.
PubMed
2) Schoffski P, et al. Lancet. 2016 ; 387 : 1629-37.
PubMed
3) Kawai A, et al. Jpn J Clin Oncol. 2016 ; 16 : 406-16.
 

第11章 悪性黒色腫

P.788 掲載の参考文献
1) 厚生労働大臣官房統計情報部. 人口動態統計. 1972～2015
 
2) Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969 ; 29 : 705-27.
PubMed
3) Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005 ; 353 : 2135-47.
PubMed
4) Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984 ; 53 : 1299-305.
PubMed
5) Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 ; 364 : 2507-16.
PubMed
6) Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 ; 363 : 711-23.
PubMed
7) 爲政大幾. 新しい免疫療法. 皮膚の悪性腫瘍 実践に役立つ最新の診断・治療. 古江増隆, ほか (編). 東京 : 中山書店 ; 2014. 87.
 
8) 山崎直也. 抗CTLA-4抗体と抗PD-1抗体による悪性黒色腫の治療開発. 大阪 : 最新医学社 ; 2015. pp.399-407.
 
9) Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 ; 364 : 2517-26.
 
10) 小野薬品工業株式会社. オプジーボ(R) 適正使用ガイド. 2015/ブリストル・マイヤーズ株式会社. ヤーボイ(R) 適正使用ガイド, 2015.
 
11) Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 ; 11 : 3887-95.
PubMed
12) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 ; 366 : 2443-54.
PubMed
13) 山崎直也. メラノーマ領域における免疫療法の最新の急速な進歩について.月刊腫瘍内科. 2014 ; 13 : 684-8.
 
14) Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 ; 372 : 2521-32.
PubMed
15) Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 ; 16 : 908-18.
PubMed
16) Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 ; 372 : 2521-32.
PubMed
17) Ashida A, Uhara H, Kiniwa Y, et al. Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci. 2012 ; 66 : 240-2.
PubMed
18) Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 ; 417 : 949-54.
PubMed
19) Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS. 2007 ; 115 : 1161-76.
PubMed
20) Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 ; 363 : 809-19.
PubMed
21) Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 ; 372 : 30-9.
PubMed
22) Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma : the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 ; 14 : 7-17.
PubMed
23) Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma : first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 ; 18 : 2444-58.
PubMed
24) Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma : final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 ; 372 : 117-26.
PubMed
25) 一般社団法人 日本皮膚悪性腫瘍学会. メラノーマ薬物療法の手引 version 1. 2017.
 
P.793 掲載の参考文献
1) Chapman PB, et al. N Engl J Med. 2011 ; 364 : 2507-16.
PubMed
2) McArthur GA, et al. Lancet Oncol. 2014 ; 15 : 323-32.
PubMed
3) Hauschild A, et al. Lancet. 2012 ; 380 : 358-65.
PubMed
4) Robert C, et al. N Engl J Med. 2015 ; 372 : 320-30.
 
P.796 掲載の参考文献
1) Hodi FS, et al. N Engl J Med. 2010 ; 363 : 711-23.
PubMed
2) Robert C, et al. N Engl J Med. 2011 ; 364 : 2517-26.
 
3) Yamazaki N, et al. Cancer Chemother Pharmacol. 2015 ; 76 : 969-75.
PubMed
P.799 掲載の参考文献
1) Robert C, et al. N Engl J Med. 2015 ; 372 : 320-30.
 
2) Ishida Y, et al. ENBO J. 1992 ; 11 : 3887-95.
 
3) Iwai Y, et al. Proc Natl Acad Sci USA. 2002 ; 99 : 12293-7.
PubMed
4) Dong H, et al. Nat Med. 2002 ; 8 : 793-800.
PubMed
P.802 掲載の参考文献
1) Ribas A, et al. JAMA. 2016 ; 315 : 1600-9.
PubMed
2) Ribas A, et al. Lancet Oncol. 2015 ; 16 : 908-18.
PubMed
3) Robert C, et al. N Engl J Med. 2015 ; 372 : 2521-32.
 
4) Elassaiss-Schaap J, et al. CPT Pharmacometrics Syst Pharmacol. 2017 ; 6 : 21-8.
PubMed
P.804 掲載の参考文献
1) McArthur GA, et al. Lancet Oncol. 2014 ; 15 : 323-32.
PubMed
2) Yamazaki N, et al. J Dermatol. 2015 ; 42 : 661-6.
PubMed
P.807 掲載の参考文献
1) Robert C, et al. N Eng J Med. 2015 ; 372 : 30-9.
 
2) Long GV, et al. N Eng J Med. 2014 ; 371 : 1877-88.
 
3) Long GV, et al. Lancet. 2015 ; 386 : 444-51.
PubMed

第12章 白血病

P.831 掲載の参考文献
1) 日本血液学会 (編). 造血器腫瘍診療ガイドライン 2013年版. 東京 : 金原出版 ; 2013.
 
2) Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults : recommendations from an international expert panel on behalf of the European LeukemiaNet. Blood. 2010 ; 115 : 453-74.
 
3) Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012 ; 36 : 4515-23.
PubMed
4) Fernandez HF, Sun Z, Yao X, et al. Anthracycline does intensification in acute myeloid leukemia. N Engl J Med. 2009 ; 361 : 1249-59.
PubMed
5) Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adults patients with previously untreated acute myeloid leukemia : the JALSG AML201 Study. Blood. 2011 ; 117 : 2358-65.
PubMed
6) Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood. 2011 ; 117 : 2366-72.
PubMed
7) Kihara R, Nagata Y, Kiyoi H, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adults acute myeloid leukemia patients. Leukemia. 2014 ; 28 : 1586-95.
PubMed
8) Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investing choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014 ; 32 : 1919-26.
 
9) Asou N, Adachi K, Tamura U, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia : the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 2001 ; Suppl 1 : S65-71.
 
10) Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 ; 369 : 111-21.
PubMed
11) Shinagawa K, Yanada M, Sakura T, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia : results from a randomized controlled trial. J Clin Oncol. 2014 ; 32 : 3729-35.
PubMed
12) Yanada M, Tsuzuki M, Fujita H, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 ; 121 : 3095-102.
PubMed
13) Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006 ; 24 : 460-6.
 
14) Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009 ; 113 : 1408-11.
 
15) Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015 ; 125 : 3702-10.
 
16) Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia. 2002 ; 16 : 1259-66.
PubMed
17) Ribera JM, Oriol A, Bethencourt C, at al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005 ; 90 : 1346-56.
PubMed
18) Katsuya H, Ishituska K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015 ; 126 : 2570-7.
 
19) Cramer P, Langerbeins P, Eichhorst B, et al. Adavnces in first-line treatment of chronic lymphocyteic leukemia : current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Fur J Haematol. 2016 ; 96 : 9-18.
 
20) Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocyteic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 ; 111 : 5446-56.
 
21) Jain N, O'Brien S. Initial treatment of CLL : integrating biology and functional status. Blood. 2015 ; 126 : 463-70.
PubMed
22) Routledge DJM, Bloor AJC. Recent advances in therapy of chronic lymphocytic leukemia. Br J Haematol. 2016 ; 174 : 351-67.
PubMed
23) Hehlmann R. CML-where do we stand in 2015?. Annal Hematol. 2015 ; 94 (Suppl 2) : S103-5.
 
24) Gambacorti-Passerini C, Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. Am J Hematol. 2015 ; 90 : 156-61.
 
25) Drucker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2005 ; 355 : 2408-17.
 
26) Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia 2016 ; 30 : 1044-54.
PubMed
27) Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION : The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016 ; 34 : 2333-40.
 
28) Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood. 2013 ; 122 : 872-84.
PubMed
29) Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia : an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015 ; 15 : 323-34.
PubMed
30) Deininger MW. Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Edu Book. 2015 ; e381-388. doi : 10.14694/EdBook_AM.2015.35.e381.
 
P.837 掲載の参考文献
1) Ohtake S, et al. Blood. 2011 ; 117 : 2358-65.
PubMed
2) Fernandez HF, et al. N Engl J Med. 2009 ; 361 : 1249-59.
PubMed
P.840 掲載の参考文献
1) Miyawaki S, et al. Blood. 2011 ; 117 : 2366-72.
PubMed
P.843 掲載の参考文献
1) Mayer RJ, et al. N Engl J Med. 1994 ; 331 : 896-903.
PubMed
2) Bloomfield CD, et al. Cancer Res. 1998 ; 58 : 4173-9.
PubMed
3) Miyawaki S, et al. Blood. 2011 ; 117 : 2366-72.
PubMed
4) Rubin EH, et al. J Clin Oncol. 1992 ; 10 : 948-53.
PubMed
P.846 掲載の参考文献
1) Trifilio SM, et al. Leuk Res. 2012 ; 36 : 394-6.
PubMed
2) Greenberg PL, et al. J Clin Oncol. 2004 ; 22 : 1078-86.
PubMed
3) Feldman EJ, et al. J Clin Oncol. 2005 ; 23 : 4110-6.
PubMed
P.848 掲載の参考文献
1) Amadori S, et al. J Clin Oncol. 2016 ; 34 : 972-9.
PubMed
2) Burnett AK, et al.J Clin Oncol. 2012 ; 30 : 3924-35.
PubMed
3) Battipaglia G, et al. Bone Marrow Transplant. 2017 ; 52 : 592-9.
PubMed
P.852 掲載の参考文献
1) Shinagawa K, et al. J Clin Oncol. 2014 ; 32 : 3729-35.
PubMed
2) Asou N, et al. Blood. 2007 ; 110 : 59-66.
PubMed
3) Ono T, et al. Cancer Sci. 2012 ; 103 : 1974-8.
PubMed
P.855 掲載の参考文献
1) Shinagawa K, et al. J Clin Oncol. 2014 ; 32 : 3729-35.
PubMed
2) Sanz MA, et al. Blood. 2009 ; 113 : 1875-91.
PubMed
3) Shinagawa K, et al. Blood. 2012 ; 120 : Abstract 410.
 
P.858 掲載の参考文献
1) Shinagawa K, et al. J Clin Oncol. 2014 ; 32 : 3729-35.
PubMed
2) Avvisati G, et al. Blood. 2011 ; 117 : 4716-25.
PubMed
3) Ohata K, et al. Thromb Res. 2012 ; 129 : 213-4.
PubMed
P.862 掲載の参考文献
1) Asou N, et al. Intern Med. 2005 ; 44 : 775-6.
PubMed
2) Yanada M, et al. Blood. 2013 ; 121 : 3095-102.
PubMed
3) Burnett AK, et al. Lancet Oncol. 2015 ; 16 : 1295-305.
PubMed
P.870 掲載の参考文献
1) 近藤英生. 思春期・若年成人急性リンパ性白血病を対象とした化学療法の安全性の検討 : JALSG ALL202-Uの中間解析. 臨床血液. 2012 ; 53 : 747-52.
 
P.875 掲載の参考文献
1) Goldstone AH, et al. Blood. 2008 ; 111 : 1827-33.
PubMed
2) Maury S, et al. N Engl J Med. 2016 ; 375 : 1044-53.
PubMed
3) Sive JI, et al. Br J Haematol. 2012 ; 157 : 463-71.
PubMed
P.879 掲載の参考文献
1) YanadaM, et al. J Clin Oncol. 2006 ; 24 : 460-6.
PubMed
2) Mizuta S, et al. Blood Cancer Journal. 2012 ; 2, e72 ; doi : 10.1038/bcj.2012.18
 
P.883 掲載の参考文献
1) 日本血液学会 (編). 造血器腫瘍ガイドライン 2013年度版. 東京 : 金原出版 ; 2013.
 
2) Hochhaus A, et al. Leukemia. 2016 ; 30 : 1044-54.
PubMed
3) Cortes JE, et al. J Clin Oncol. 2016 ; 34 : 2333-40.
PubMed
P.886 掲載の参考文献
1) 日本血液学会 (編). 造血器腫瘍ガイドライン 2013年度版. 東京 : 金原出版 ; 2013.
 
2) Baccarani M, et al. Blood. 2013 ; 122 : 872-84.
PubMed
3) Jiang Q, et al. Blood. 2011 ; 117 : 3032-40.
PubMed
P.889 掲載の参考文献
1) 日本血液学会 (編). 造血器腫瘍ガイドライン 2013年度版. 東京 : 金原出版 ; 2013.
 
2) Sausele S, et al. Ann Hematol. 2015 ; 94 Suppl 2 : S159-65.
 
3) Ohashi K, et al. Int J Hematol. 2014 ; 100 : 296-306.
PubMed
P.892 掲載の参考文献
1) Fenaux P, et al. Lancet Oncol. 2009 ; 10 : 223-32.
PubMed
2) Lyons RM, et al. J Clin Oncol. 2009 ; 27 : 1850-6.
PubMed
3) Itzykson R, et al. Blood. 2011 ; 117 : 403-11.
 
P.895 掲載の参考文献
1) List A, et al. N Engl J Med. 2006 ; 355 : 1456-65.
PubMed
2) List AF, et al. Leukemia. 2014 ; 28 : 1033-40.
PubMed
3) Fenaux P, et al. Blood. 2011 ; 118 : 3765-76.
PubMed
P.898 掲載の参考文献
1) Li JM, et al. Int J Hematol. 2005 ; 82 : 48-54.
PubMed
2) Wei G, et al. J Hematol Oncol. 2011 ; 4 : 46.
 
3) Minakata D, et al. Leuk Res. 2016 ; 42 : 82-7.
PubMed
P.901 掲載の参考文献
1) Burnett AK, et al. Cancer. 2007 ; 109 : 1114-24.
PubMed
2) Fenaux P, et al. J Clin Oncol. 2010 ; 28 : 562-9.
PubMed
3) Dohner H, et al. Blood. 2014 ; 124 : 1426-33.
PubMed
P.904 掲載の参考文献
1) Tsukasaki K, et al. J Clin Oncol. 2007 ; 25 : 5458-64.
PubMed
2) 塚崎邦弘. 臨床血液. 2010 ; 51 : 275-86.
 
P.907 掲載の参考文献
1) Ishida T, et al. J Clin Oncol. 2012 ; 30 : 837-42.
PubMed
2) 米倉健太郎. 血液内科. 2015 ; 40 : 467-73.
 
3) ポテリジオ(R) 点滴静注 20 mg 適正使用ガイド. 協和発酵キリン株式会社.
 
P.910 掲載の参考文献
1) Ishida T, et al. Br J Haematol. 2015 ; 169 : 672-82.
PubMed
2) 塚崎邦弘. 臨床血液. 2010 ; 51 : 275-86.
 
3) Ishida T, et al. J Clin Oncol. 2012 ; 30 : 837-42.
PubMed
4) 米倉健太郎. 血液内科. 2015 ; 40 : 467-73.
 
P.912 掲載の参考文献
1) Ishida T, et al. J Clin Oncol. 2016 ; 34 : 4086-93.
PubMed
2) Dredge K, et al. J Immunol. 2002 ; 168 : 4914-9.
PubMed
3) Toumishey E, et al. Cancer. 2015 ; 121 : 716-23.
PubMed
P.915 掲載の参考文献
1) Fischer K, et al. Blood. 2016 ; 127 : 208-15.
PubMed
2) Robak T, et al. J Clin Oncol. 2010 ; 28 : 1756-65.
PubMed
3) Keating MJ, et al. Blood. 1998 ; 92 : 1165-71.
PubMed
P.918 掲載の参考文献
1) Eichhorst B, et al. Lancet Oncol. 2016 ; 17 : 928-42.
PubMed
2) Fischer K, et al. J Clin Oncol. 2011 ; 29 : 3559-66.
 
P.921 掲載の参考文献
1) Wierda WG, et al. J Clin Oncol. 2010 ; 28 : 1749-55.
PubMed
2) Osterborg A, et al. Haematologica. 2015 ; 100 : e311-4.
PubMed
3) Hillmen P, et al. Lancet. 2015 ; 385 : 1873-83.
PubMed
P.924 掲載の参考文献
1) Byrd JC, et al. N Engl J Med. 2014 ; 371 : 213-23.
PubMed
2) Burger JA, et al. N Engl J Med. 2015 ; 373 : 2425-37.
PubMed
3) Byrd JC, et al. Blood. 2015 ; 125 : 2497-506.
PubMed
P.927 掲載の参考文献
1) Hillmen P, et al. J Clin Oncol. 2007 ; 25 : 5616-23.
PubMed
2) Pettitt AR, et al. J Clin Oncol. 2012 ; 30 : 1647-55.
PubMed
3) Keating MJ, et al. Blood. 2002 ; 99 : 3554-61.
PubMed
P.930 掲載の参考文献
1) Goodman GR, et al. J Clin Oncol. 2003 ; 21 : 891-6.
PubMed
2) Ogura M, et al. Int J Hematol. 2004 ; 80 : 267-77.
PubMed
3) Sigal DR, et al. Blood. 2010 ; 116 : 2884-96.
 

第13章 多発性骨髄腫

P.944 掲載の参考文献
1) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : a report of the International Myeloma Working Group. Br J Haematol. 2003 ; 121 : 749-57.
 
2) Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 ; 15 : e538-48.
 
3) Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005 ; 106 : 812-7.
PubMed
4) Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008 ; 111 : 785-9.
PubMed
5) Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008 ; 113 : 1588-95.
PubMed
6) Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 ; 369 : 438-47.
PubMed
7) Auner HW, Garderet L, Kroger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol. 2015 ; 171 : 453-62.
PubMed
8) Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma : A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 ; 13 : 183-96.
PubMed
9) Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma : up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998 ; 92 : 3131-6.
PubMed
10) Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 ; 371 : 895-905.
PubMed
11) Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 ; 16 : 1617-29.
PubMed
12) Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011 ; 117 : 6721-7.
PubMed
13) Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102) : a phase 3 biological assignment trial. Lancet Oncol. 2011 ; 12 : 1195-203.
PubMed
14) Gahrton G, Iacobelli S, Bjorkstrand B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma : long-term results of the EBMT-NMAM2000 study. Blood. 2013 ; 121 : 5055-63.
PubMed
15) 日本血液学会 (編). 造血器腫瘍診療ガイドライン 2013年版. 東京 : 金原出版 ; 2013.
 
16) Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 ; 117 : 6063-73.
 
17) Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited : IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 ; 114 : 1729-35.
PubMed
18) Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003 ; 349 : 2495-502.
PubMed
19) Wang Y, Yang F, Shen Y, et al. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma : A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2015 ; 108.
 
20) San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 ; 359 : 906-17.
PubMed
21) Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 ; 371 : 906-17.
PubMed
22) Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma : an open-label randomised controlled trial. Lancet Oncol. 2010 ; 11 : 29-37.
PubMed
23) Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma : meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011 ; 118 : 1239-47.
PubMed
24) Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 ; 32 : 587-600.
 
25) Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016 ; 34 : 1544-57.
 
26) Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials : report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 ; 117 : 4691-5.
PubMed
27) Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma : recommendations of the International Myeloma Working Group. Leukemia. 2016 ; 30 : 1005-17.
 
28) Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma : final time-to-event results of the APEX trial. Blood. 2007 ; 110 : 3557-60.
PubMed
29) Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 ; 23 : 2147-52.
PubMed
30) San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 ; 14 : 1055-66.
 
31) Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 ; 27 : 5713-9.
PubMed
32) Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013 ; 31 : 2347-57.
 
33) Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009 ; 49 : 1211-25.
PubMed
P.952 掲載の参考文献
1) San Miguel JF, et al. N Engl J Med. 2008 ; 359 : 906-17.
PubMed
2) Bringhen S, et al. Blood. 2010 ; 116 : 4745-53.
PubMed
3) San Miguel JF, et al. J Clin Oncol. 2013 ; 31 : 448-55.
PubMed
P.955 掲載の参考文献
1) Rajkumar SV, et al. Lancet Oncol. 2010 ; 11 : 29-37.
PubMed
2) Benboubker L, et al. N Engl J Med. 2014 ; 371 : 906-17.
PubMed
3) Palumbo A, et al. Lancet Oncol. 2014 ; 15 : 333-42.
PubMed
P.958 掲載の参考文献
1) Harousseau JL, et al. J Clin Oncol. 2010 ; 28 : 4621-9.
PubMed
2) Niesvizky R, et al. J Clin Oncol. 2015 ; 33 : 3921-9.
PubMed
P.960 掲載の参考文献
1) Reader CB, et al. Leukemia. 2009 ; 23 : 1337-41.
 
2) Kumar S, et al. Blood. 2012 ; 119 : 4375-82.
PubMed
3) Stewart AK, et al. Blood. 2009 ; 114 : 5436-43.
PubMed
P.963 掲載の参考文献
1) Attal M, et al. N Engl J Med. 1996 ; 335 : 91-7.
PubMed
2) Moreau P, et al. Blood. 2002 ; 99 : 731-5.
PubMed
3) Koreth J, et al. Biol Blood Marrow Transplant. 2007 ; 13 : 183-96.
PubMed
4) Palumbo A, et al. Blood. 2004 ; 104 : 3052-7.
PubMed
5) Dimopoulos MA, et al. J Clin Oncol. 2016 ; 34 : 1544-57.
PubMed
6) Attal M, et al. Blood. 2015 ; 126 : Abstract 391.
 
P.966 掲載の参考文献
1) Richardson PG, et al. Blood. 2014 ; 123 : 1461-9.
PubMed
2) Dimopoulos MA, et al. Leukemia. 2010 ; 24 : 1769-78.
PubMed
3) Richardson PG, et al. Blood. 2010 ; 116 : 679-86.
PubMed
4) Durie B, et al. Blood. 2015 ; 126 : Abstract 25.
 
P.969 掲載の参考文献
1) Palumbo A, et al. Ann Oncol. 2008 ; 19 : 1160-5.
 
2) Takamatsu, et al. Int J Hematol. 2013 ; 98 : 179-85.
PubMed
3) Sonneveld P, et al. J Clin Oncol. 2012 ; 30 : 2946-55.
PubMed
P.972 掲載の参考文献
1) Barlogie B, et al. N Engl J Med. 1984 ; 31 : 1353-6.
 
2) Alexanian R, et al. Ann Intern Med. 1986 ; 105 : 8-11.
PubMed
P.975 掲載の参考文献
1) Glasmacher A, et al. Br J Haematol. 2006 ; 132 : 584-93.
PubMed
2) von Lilienfeld-Toal M, et al. Eur J Haematol. 2008 ; 81 : 247-52.
PubMed
3) Madan S, et al. Blood. 2011 ; 118 : 1763-5.
PubMed
4) Murakami H, et al. Int J Hematol. 2009 ; 89 : 636-41.
PubMed
P.978 掲載の参考文献
1) San Miguel J, et al. Lancet Oncol. 2013 ; 14 : 1055-66.
 
2) Ichinohe T, et al. Exp Hematol Oncol. 2015 ; 5 : 11.
PubMed
P.981 掲載の参考文献
1) San-Miguel JF, et al. Lancet Oncol. 2014 ; 15 : 1195-206.
PubMed
2) Richardson PG, et al. Blood. 2013 ; 122 : 2331-7.
PubMed
3) Richardson PG, et al. Blood. 2016 ; 127 : 713-21.
PubMed
P.984 掲載の参考文献
1) Stewart AK, et al. N Engl J Med. 2015 ; 372 : 142-52.
PubMed
2) Wang M, et al. Blood. 2013 ; 122 : 3122-8.
PubMed
3) Watanabe T, et al. Br J of Haematology. 2016 ; 172 : 745-56.
PubMed
P.987 掲載の参考文献
1) Dimopoulos MA, et al. Lancet Oncol. 2016 ; 17 : 27-38.
 
2) Moreau P, et al. Leukemia. 2017 ; 31 : 115-22.
PubMed
3) Chng WJ, et al. Leukemia. 2017 ; 31 : 1368-74.
PubMed
4) Dimopoulos MA, et al. Lancet Oncol. 2017 ; 18 : 1327-37.
PubMed
P.990 掲載の参考文献
1) Lonial S, et al. N Engl J Med. 2015 ; 373 : 621-31.
PubMed
2) Hsi ED, et al. Clin Cancer Res. 2008 ; 14 : 2775-84.
PubMed
3) Suzuki K, et al. Blood Cancer J. 2017 ; 7 : e540.
PubMed
P.993 掲載の参考文献
1) Dimopoulos MA, et al. N Engl J Med. 2016 ; 375 : 1319-31.
PubMed
2) Krejcik J, et al. Blood. 2016 ; 128 : 384-94.
PubMed
3) Nijhof IS, et al. Clin Cancer Res. 2015 ; 21 : 2802-10.
PubMed
P.996 掲載の参考文献
1) Palumbo A, et al. N Engl J Med. 2016 ; 375 : 754-66.
PubMed
2) van de Donk NWCJ, et al. Blood. 2018 ; 131 : 13-29.
PubMed
P.999 掲載の参考文献
1) Moreau P, et al. N Engl J Med. 2016 ; 374 : 1621-34.
PubMed
2) Kumar SK, et al. Lancet Oncol. 2014 ; 15 : 1503-12.
PubMed
3) Richardson PG, et al. Blood. 2014 ; 124 : 1038-46.
PubMed
4) Kumar SK, et al. Blood. 2014 ; 124 : 1047-55.
PubMed
5) Avet-Loiseau H, et al. Blood. 2017 ; 130 : 2610-8.
PubMed

第14章 悪性リンパ腫

P.1013 掲載の参考文献
1) Connors JM, Jurczak W, Straus DJ, et al ; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 ; 378 : 331-44.
PubMed
2) Chen R, Gopal AK, Smith SE et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016 ; 128 : 1562-6.
PubMed
3) Perrot A, Monjanel H, Bouabdallah R, et al ; Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas : a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016 ; 101 : 466-73.
PubMed
4) Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 ; 23 : 4117-26.
 
5) Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005 ; 23 : 5027-33.
PubMed
6) Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 ; 7 : 379-91.
PubMed
7) Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 ; 109 : 1857-61.
 
8) Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 ; 9 : 105-16.
PubMed
9) Persky DO, Unger JM, Spier CM, et al. Phase 2 study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma : Southwest Oncology Group study 0014. J Clin Oncol. 2008 ; 26 : 2258-63.
 
10) Haioun C, Itti E, Rahmouni A, et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma : an early prognostic tool for predicting patient outcome. Blood. 2005 ; 106 : 1376-81.
PubMed
11) Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 ; 24 : 3121-7.
PubMed
12) Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007 ; 109 : 4930-5.
PubMed
13) Liu YY, Leboeuf C, Shi JY, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood. 2007 ; 110 : 339-44.
 
14) Fu K, Weisenburger DD, Choi WW, et al. Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2008 ; 26 : 4587-94.
PubMed
15) Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab : an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008 ; 9 : 435-44.
PubMed
16) Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma : an international, randomised, open-label, phase 3 study. Lancet. 2016 ; 387 : 770-8.
 
17) Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 ; 127 : 1559-63.
PubMed
18) Hagberg H, Gisselbrecht C ; CORAL study group. Randomised phase 3 study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not. an update of the CORAL study. Ann Oncol. 2006 ; 17 (Suppl 4) : iv31-32.
 
19) Tarella C, Zanni M, Magni M, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma : a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008 ; 26 : 3166-75.
PubMed
20) Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007 ; 110 : 54-8.
 
21) Sehn LH, Chua N, Mayer J,et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN) : a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 ; 17 : 1081-93.
PubMed
22) Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase 2 trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006 ; 24 : 3880-6.
PubMed
23) Ogura M, Tsukasaki K, Nagai H, et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci. 2012 ; 103 : 1290-5.
PubMed
24) Maruyama D, Nagai H, Maeda Y, et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017 ; 108 : 2061-8.
PubMed
25) Maruyama D, Tobinai K, Ogura M, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma : a phase I/II and pharmacokinetics study. Int J Hematol. 2017 ; 106 : 655-65.
PubMed
26) Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation : Extended Follow-Up of the Multicohort Single-Arm Phase II Check-Mate 205 Trial. J Clin Oncol. 2018 : JCO2017760793.
 
P.1019 掲載の参考文献
1) Feugier P, et al. J Clin Oncol. 2005 ; 23 : 4117-26.
PubMed
2) Habermann MT, et al. J Clin Oncol. 2006 ; 24 : 3121-7.
PubMed
3) Pfreundschuh M, et al. Lancet Oncol. 2008 ; 9 : 105-16.
PubMed
4) Pfreundschuh M, et al. Lancet Oncol. 2006 ; 7 : 379-91.
PubMed
P.1021 掲載の参考文献
1) Marcus R, et al. J Clin Oncol. 2008 ; 26 : 4579-86.
 
P.1024 掲載の参考文献
1) Kewalramani T, et al. Blood. 2004 ; 103 : 3684-8.
PubMed
2) Gisselbercht C, et al. J Clin Oncol. 2010 ; 28 : 4184-90.
 
3) Hertzberg MS, et al. Ann Oncol. 2006 ; 17 (suppl 4) : iv25-iv30.
 
P.1028 掲載の参考文献
1) Witzig TE, et al. J Clin Oncol. 1999 ; 17 : 3793-803.
PubMed
2) Gordon LI, et al. Clin Lymphoma. 2004 ; 5 : 98-101.
PubMed
3) Witzig TE, et al. J Clin Oncol. 2002 ; 20 : 3262-9.
PubMed
4) Watanabe T, et al. Cancer Sci. 2005 ; 96 : 903-10.
PubMed
5) Tobinai K, et al. Cancer Sci. 2009 ; 100 : 158-64.
PubMed
6) Hainsworth JD, et al. Clin Lymphoma Myeloma. 2009 ; 9 : 223-8.
PubMed
7) Jacobs SA, et al. Clin Cancer Res. 2008 ; 14 : 7088-94.
PubMed
8) Morschhauser F, et al. J Clin Oncol. 2008 ; 26 : 5156-64.
PubMed
9) Hagenbeek A, et al. Blood. 2010 ; 116 : Abstract 594.
 
P.1031 掲載の参考文献
1) Kahl BS, et al. Cancer. 2010 ; 116 : 106-14.
PubMed
2) Ohmachi K, et al. Cancer Sci. 2010 ; 101 : 2059-64.
PubMed
3) Knauf WU, et al. J Clin Oncol. 2009 ; 27 : 4378-84.
PubMed
4) Robinson KS, et al. J Clin Oncol. 2008 ; 26 : 4473-9.
PubMed
P.1034 掲載の参考文献
1) Philip T, et al. N Engl J Med. 1995 ; 333 : 1540-5.
PubMed
2) Crump M, et al. J Clin Oncol. 2014 ; 32 : 3490-6.
 
3) Gisselbrecht C, et al. J Clin Oncol. 2010 ; 28 : 4184-90.
PubMed
P.1037 掲載の参考文献
1) Velasquez WS, et al. J Clin Oncol. 1994 ; 12 : 1169-76.
PubMed
2) Akhtar S, et al. Leuk Lymphoma. 2008 ; 49 : 769-78.
PubMed
3) Martin A, et al. Haematologica. 2008 ; 93 : 1829-36.
PubMed
P.1040 掲載の参考文献
1) Dunleavy K, et al. ASH Annual Meeting. 2014 ; abstract 395
 
2) Dunleavy K, et al. N Engl J Med. 2013 ; 369 : 1915-25.
 
3) Dunleavy K, et al. ASH Annual Meeting. 2011 ; 118. abstract 1618
 
4) Vose J, et al. J Clin Oncol. 2008 ; 26 : 4121-30.
 
P.1043 掲載の参考文献
1) Baetz T, et al. Ann Oncol. 2003 ; 14 : 1762-67.
PubMed
2) Curmp M, et al. J Clin Oncol. 2014 ; 32 : 3490-7.
 
3) Dumontet C. et al. Br J Haematol. 2001 ; 113 : 772-8.
PubMed
P.1048 掲載の参考文献
1) Romaguera JE, et al. J Clin Oncol. 2005 ; 23 : 7013-23.
PubMed
2) Romaguera JE, et al. Br J Haematol. 2010 ; 150 : 200-8.
PubMed
3) Thomas DA, et al. Cancer. 2006 ; 106 : 1569-80.
PubMed
4) Tam CS, et al. Blood. 2009 ; 113 : 4144-52.
PubMed
5) Robak T, et al. N Engl J Med. 2015 ; 372 : 944-53.
PubMed
P.1051 掲載の参考文献
1) Ishida T, et al. J Clin Oncol. 2012 ; 30 : 837-42.
PubMed
2) Ogura M, et al. J Clin Oncol. 2014 ; 32 : 1-8.
PubMed
3) Shinkawa T, et al. J Biol Chem. 2003 ; 278 : 3466-73.
PubMed
4) Savage KJ, et al. Ann Oncol. 2004 ; 15 : 1467-75.
PubMed
5) Jones D, et al. Blood. 2000 ; 96 : 685-90.
PubMed
P.1054 掲載の参考文献
1) Duvic M, et al. Blood. 2007 ; 109 : 31-9.
PubMed
2) Kelly WK, et al. J Clin Oncol. 2005 ; 23 : 3923-31.
PubMed
3) O'Connor OA. Eur J Haematol. 2005 ; 66 (Suppl) : 150-8.
 
4) Garcia-Manero G, et al. Blood. 2005 ; 106 : 785a.
 
5) Kelly WK, et al. Clin Cancer Res. 2003 ; 9 : 3578-88.
PubMed
6) O'Connor OA, et al. J Clin Oncol. 2005 ; 24 : 166-73.
PubMed
7) Duvic M, et al. J Am Acad Dermatol. 2003 ; 49 : 35-49.
PubMed
P.1058 掲載の参考文献
1) Canellos GP, et al. N Engl J Med. 1992 ; 327 : 1478-84.
PubMed
2) Ogura M, et al. Int J Hematol. 2010 ; 92 : 713-24.
 
3) Engert A, et al. N Engl J Med. 2010 ; 363 : 640-52.
PubMed
4) Younes A, et al. Lancet Oncol. 2013 ; 14 : 1348-56.
PubMed
P.1061 掲載の参考文献
1) Younes A, et al. J Clin Oncol. 2012 ; 30 : 2183-9.
PubMed
2) Pro B, et al. J Clin Oncol. 2012 ; 30 : 2190-6.
PubMed
3) Ogura M, et al. Cancer Sci. 2014 ; 105 : 840-6.
PubMed
P.1063 掲載の参考文献
1) Anas Y, et al. J Clin Oncol. 2016 ; 34 suppl : abstr 7535.
 
2) Ansel SM, et al. N Engl J Med. 2015 ; 372 : 311-9.
 

第15章 化学療法の副作用に対する薬物による支持療法

P.1077 掲載の参考文献
1) 日本臨床腫瘍学会 (編). 発熱性好中球減少症 (FN) 診療ガイドライン. 東京 ; 南江堂 ; 2012.
 
2) Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000 ; 18 : 3038-51.
PubMed
3) Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia : validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 ; 33 : 465-71.
 
4) Watanabe T, Tobinai K, Shibata T et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma : JCOG 0203 trial. J Clin Oncol. 2011 ; 29 : 3990-8.
 
5) 厚生労働省. 血液製剤の使用指針 (改定版).
 
6) NCCN GUIDELINES FOR SUPPORTIVE CARE, Cancer- and Chemotherapy-Induced Anemia Version 2. 2016
 
7) 日本癌治療学会 (編). 制吐薬適正使用ガイドライン. 東京 ; 金原出版 : 2015.
 
8) Suzuki K, Yamanaka T, Hashimoto H, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy : TRIPLE study. Ann Oncol. 2016 ; 27 : 1601-6.
PubMed
9) Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy : a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009 ; 10 : 115-24.
PubMed
10) Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 ; 375 : 134-42.
PubMed
11) Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 ; 22 : 2918-26.
PubMed
12) Mori K, Kondo T, Kamiyama Y, et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003 ; 51 : 403-6.
PubMed
13) Takeda Y, Kobayashi K, Akiyama Y, et al. Prevention of irinotecan (CPT-11) -induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer. 2001 ; 92 : 269-75.
PubMed
14) リツキシマブ インタビューフォーム.
 
15) Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999 ; 94 : 2217-24.
PubMed
16) Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008 ; 358 : 1109-17.
PubMed
17) 厚生労働省. 重篤副作用疾患別対応マニュアル. アナフィラキシー. (平成20年3月)
 

書評

最近チェックした商品履歴

Loading...